Lactobacillus acidophilus to increase agmatine production of microbiota

By using isolated probiotics and arginine in the gastrointestinal tract to catalyze the production of guanidine, the problems of local effect assessment and high cost of guanidine supplementation are solved, realizing the health benefits in the gastrointestinal tract.

CN118891052APending Publication Date: 2024-11-01SOCIETE DES PRODUITS NESTLE SA
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202280080262.6
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2021-12-09
Filing Date
2022-12-07
Publication Date
2024-11-01

AI Technical Summary

Technical Problem

In the existing technology, guanidine supplementation is mainly achieved through oral synthesis. However, after absorption in the small intestine, it is converted in the liver, making it impossible to assess the local gastrointestinal effects. Furthermore, the production cost is high, and there is a lack of methods to increase the production of guanidine by increasing the microbiome.

Method used

Using isolated probiotics, such as Lactobacillus acidophilus NCC 2628, NCC 2766, NCC 2775 and NCC 2619, combined with arginine, the composition catalyzes the production of guanidine amine in the gastrointestinal tract through arginine decarboxylase. The composition contains starch source, protein source, lipid source, prebiotics, etc., to ensure the colonization and survival of probiotics in the gastrointestinal tract.

Benefits of technology

It effectively produces guanidine in the gastrointestinal tract, providing health benefits such as pain relief, anti-aging, neuroprotection, anti-depression, improved vasodilation and metabolic health, while avoiding the liver conversion problems of synthetic guanidine and reducing costs.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0004873137000000011
    Figure BDA0004873137000000011
  • Figure BDA0004873137000000311
    Figure BDA0004873137000000311
  • Figure BDA0004873137000000331
    Figure BDA0004873137000000331
Patent Text Reader

Abstract

Disclosed are probiotics, compositions, and methods for producing agmatine using a microbiota; the present invention relates to isolated probiotics, and more specifically, disclosed are isolated probiotics for increasing the production of agmatine and / or polyamines in the gastrointestinal tract of a subject, compositions and methods comprising these isolated probiotics, to provide certain health benefits to the subject, such as to increase the production of agmatine and / or polyamines in the gastrointestinal tract of a subject. Such as pain relief, anti-aging effects, neuroprotection and anti-depression effects, improved vasodilation and metabolic health, improved cellular health, reduced age-related memory loss, and / or longevity. The isolated probiotic is capable of colonizing and surviving in the gastrointestinal tract of the subject, and is capable of converting arginine to agmatine in the gastrointestinal tract of the subject.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present disclosure generally relates to probiotics, compositions and methods for producing agmatine using a microbiota, and more specifically, to probiotics, compositions and methods for increasing the production of agmatine and / or polyamines in the gastrointestinal tract of a subject so as to provide certain health benefits to the subject, such as pain relief, anti-aging effects, neuroprotection and anti-depressant effects, improved vasodilation and metabolic health, improved cellular health, reduced age-related memory loss and lifespan. The composition comprises probiotics capable of colonizing and surviving in the gastrointestinal tract of a subject and capable of converting arginine to agmatine in the gastrointestinal tract of the subject. Background Art

[0002] Agmatine, also known as (4-aminobutyl)guanidine, is an aminoguanidine having a chemical structure as shown in Formula I below. Agmatine is a natural compound produced by the decarboxylation of the amino acid arginine, also known as decarboxylated arginine. Agmatine is one of the precursors of polyamines such as putrescine (diamine), spermidine (triamine) and spermine (tetraamine) in plant cells, prokaryotic cells and some mammalian cells.

[0003]

[0004] Polyamines such as putrescine, spermidine, and spermine are essential for normal cell growth and survival. Spermidine is a cytoprotectant and inducer of autophagy, and its supplementation has been associated with anti-aging effects in preclinical and clinical trials [1,2]. Higher systemic and urinary polyamine levels are associated with growth in healthy children, but in the context of cancer, these molecules may also be associated with tumor progression [3,4].

[0005] In addition to being an intermediate in the production of polyamines, agmatine also induces a variety of physiological and pharmacological effects on the central nervous system and other organs [5,6]. Supplementation with synthetic agmatine has resulted in several health benefits. The most described and demonstrated benefits are the neuroprotective and antidepressant effects of agmatine, which are supported by several preclinical studies using animal models of cerebral ischemia, hypoxia, drug-based toxicity, or behavioral tests predicting antidepressant activity (tail suspension and forced swim tests) [7,8]. Clinical trials and several preclinical studies conducted on patients with radiculopathy have also well demonstrated the effects of agmatine supplementation on pain relief [6,7]. Early evidence (based on in vitro or ex vivo experiments) found effects of agmatine on vasodilation, improved metabolic health (stimulation of fatty acid oxidation, reduced lipid peroxidation, improved insulin signaling), and cellular health (reduction of oxidative stress, cytoprotective effects, proliferative effects, and antiproliferative effects) [5,6].

[0006] Agmatine and its downstream byproducts are associated with a series of potential health benefits, including pain relief, life span and aging improvement. So far, the supplementation of agmatine is carried out by oral administration of synthetic forms of agmatine. Other alternatives to provide agmatine are through food, in the form of a derivative form of agmatine found in plant-based products. However, these forms of agmatine are absorbed by the small intestine and converted in the liver before reaching the bloodstream in the form of downstream polyamines. Since agmatine is all converted, its direct effect cannot be evaluated. When there is the possibility of agmatine that enhances the production of microbiota, the local effect of agmatine at the gastrointestinal level depends on blood circulation. In addition, compared with the cost of arginine (the upstream source molecule of agmatine), it is expensive to produce synthetic agmatine. There is no method for increasing the production of agmatine by microbiota.

[0007] Applicants of the present disclosure have identified probiotics, compositions and methods for enhancing agmatine production using microbiota in the gastrointestinal tract of a subject. Summary of the invention

[0008] The present disclosure provides probiotics, compositions and methods for producing agmatine using a microbiota, and more particularly, relates to isolated probiotics, compositions and methods for increasing the production of agmatine and / or polyamines in the gastrointestinal tract of a subject so as to provide certain health benefits to the subject, such as pain relief, anti-aging effects, neuroprotective and anti-depressant effects, improved vasodilation and metabolic health, improved cellular health and longevity.

[0009] In one aspect, the present disclosure provides a method for improving pain relief, anti-aging effects, neuroprotective and antidepressant effects, improved vasodilation and metabolic health, improved cellular health, and lifespan, and reducing age-related memory loss in a subject in need thereof by increasing the production of agmatine in the gastrointestinal tract of the subject using a local microbiota, the method comprising administering to the subject a composition comprising: an isolated probiotic; and arginine, wherein the isolated probiotic is a bacterial strain having at least 90%, preferably at least 95% sequence identity to one or more of Lactobacillus acidophilus NCC 2628 (CNCM I-2453), Lactobacillus acidophilus NCC 2766 (CNCM I-3848), Lactobacillus acidophilus NCC 2775 (CNCM I-3851), and Lactobacillus acidophilus NCC 2619 (ATCC 700396).

[0010] In one embodiment, the composition further comprises one or more of a starch source, a protein source, a lipid source, a prebiotic source (such as FOS, GOS), vitamins, sugars, salts, spices, seasonings, minerals and flavorings.

[0011] In one embodiment, the isolated probiotic is a strain of Lactobacillus acidophilus.

[0012] In one embodiment, the isolated probiotic is a Lactobacillus acidophilus strain selected from Lactobacillus acidophilus NCC 2628 (CNCM 1-2453), Lactobacillus acidophilus NCC 2766 (CNCM 1-3848), Lactobacillus acidophilus NCC 2775 (CNCM 1-3851), Lactobacillus acidophilus NCC2619 (ATCC 700396) and combinations thereof.

[0013] In one embodiment, the isolated probiotic uses arginine decarboxylase (ADC) and local microbiota to catalyze the production of agmatine from arginine in the gastrointestinal tract of the subject, wherein the concentration of agmatine in the gastrointestinal tract of the subject is at least 20 μM 24 hours after administration of the composition.

[0014] In one embodiment, the concentration of agmatine in the gastrointestinal tract of a subject is at least 100 μM about 24 hours after administration of the composition.

[0015] In one embodiment, the composition is in the form of a dry powder, and the isolated probiotic bacteria are filled into the composition.

[0016] In one embodiment, the isolated probiotic is active in the composition.

[0017] In one embodiment, the composition is in the form of a capsule.

[0018] In one embodiment, the isolated probiotic bacteria in the capsule have the ability to survive in a pH 1.5 fluid environment for at least 30 minutes.

[0019] In one embodiment, the isolated probiotic bacteria in the capsule are able to survive in a pH 3.5 fluid environment for at least 90 minutes.

[0020] In one embodiment, the isolated probiotic bacteria is able to survive in a pH 1.5 fluid environment for at least 10 minutes.

[0021] In one embodiment, the isolated probiotic bacteria is able to survive in a pH 3.5 fluid environment for at least 60 minutes.

[0022] In one embodiment, the gastrointestinal tract of the subject is the lower gastrointestinal tract of the subject.

[0023] In one embodiment, the gastrointestinal tract of the subject is the large intestine of the subject.

[0024] In one embodiment, the composition is administered to a subject in an amount effective to provide the subject with a daily dose of the isolated probiotic in an amount of at least 7 million CFU and a daily dose of arginine in an amount of at least 3 g / L.

[0025] In one embodiment, the subject is a human.

[0026] In one embodiment, the method further comprises administering a prebiotic to the subject either before or after administering the composition.

[0027] In one aspect, the present disclosure provides a composition for improving pain relief, anti-aging effects, neuroprotective and antidepressant effects, improved vasodilation and metabolic health, improved cellular health, and lifespan, and reducing age-related memory loss in a subject in need thereof by increasing the production of agmatine in the gastrointestinal tract of the subject using a local microbiota, the composition comprising: an isolated probiotic; and arginine, wherein the isolated probiotic is a bacterial strain having at least 90%, preferably at least 95% sequence identity to one or more of Lactobacillus acidophilus NCC 2628 (CNCM I-2453), Lactobacillus acidophilus NCC 2766 (CNCM I-3848), Lactobacillus acidophilus NCC 2775 (CNCM I-3851), and Lactobacillus acidophilus NCC 2619 (ATCC 700396), wherein the isolated probiotic has the ability to colonize and survive in the gastrointestinal tract of the subject and produce agmatine from at least 20 μM arginine in the gastrointestinal tract of the subject using the local microbiota.

[0028] In one embodiment, the composition further comprises one or more of a starch source, a protein source, a lipid source, a prebiotic source, vitamins, sugars, salts, spices, seasonings, minerals and flavoring agents.

[0029] In one embodiment, the isolated probiotic is active in the composition.

[0030] In one embodiment, the isolated probiotic bacteria is able to survive in a pH 1.5 fluid environment for at least 10 minutes.

[0031] In one embodiment, the isolated probiotic bacteria is able to survive in a pH 3.5 fluid environment for at least 60 minutes.

[0032] In one embodiment, the composition is in the form of a capsule.

[0033] In one embodiment, the isolated probiotic bacteria in the capsule are able to survive in a pH 1.5 fluid environment for at least 30 minutes.

[0034] In one embodiment, the isolated probiotic bacteria in the capsule are able to survive in a pH 3.5 fluid environment for at least 90 minutes.

[0035] In one embodiment, the composition is in the form of a dry powder, and the isolated probiotic bacteria are filled into the composition.

[0036] In one embodiment, the isolated probiotic is a strain of Lactobacillus acidophilus.

[0037] In one embodiment, the isolated probiotic is a Lactobacillus acidophilus strain selected from Lactobacillus acidophilus NCC 2628 (CNCM 1-2453), Lactobacillus acidophilus NCC 2766 (CNCM 1-3848), Lactobacillus acidophilus NCC 2775 (CNCM 1-3851), Lactobacillus acidophilus NCC2619 (ATCC 700396) and combinations thereof.

[0038] In one aspect the present disclosure provides an isolated probiotic for improving pain relief, anti-aging effects, neuroprotective and antidepressant effects, improved vasodilation and metabolic health, improved cellular health, and lifespan, and reducing age-related memory loss in a subject in need thereof by increasing the production of agmatine in the gastrointestinal tract of the subject using a local microbiota. The isolated probiotic is a bacterial strain having at least 90%, preferably 95%, sequence identity to one or more of Lactobacillus acidophilus NCC 2628 (CNCM I-2453), Lactobacillus acidophilus NCC 2766 (CNCM I-3848), Lactobacillus acidophilus NCC 2775 (CNCM I-3851), and Lactobacillus acidophilus NCC 2619 (ATCC700396), wherein the isolated probiotic has the ability to colonize and survive in the gastrointestinal tract of a subject and produce at least μM agmatine from arginine in the gastrointestinal tract of a subject using a local microbiota.

[0039] In one embodiment, the isolated probiotic is a bacterial strain selected from Lactobacillus acidophilus NCC 2628 (CNCM 1-2453), Lactobacillus acidophilus NCC 2766 (CNCM 1-3848), Lactobacillus acidophilus NCC 2775 (CNCM 1-3851), Lactobacillus acidophilus NCC2619 (ATCC 700396) and combinations thereof.

[0040] In one embodiment, the isolated probiotic is capable of producing agmatine from arginine using arginine decarboxylase (ADC) and local microflora in the gastrointestinal tract of a subject at a pH between about 4.0 and about 8.0.

[0041] In one embodiment, the isolated probiotic has the ability to increase the production of agmatine from arginine in the gastrointestinal tract of a subject by at least 50% using the local microbiota.

[0042] In one embodiment, the isolated probiotic has the ability to increase the production of agmatine from arginine in the gastrointestinal tract of a subject by at least 50% using arginine decarboxylase (ADC) and local microbiota in the presence of the cofactor pyridoxal 5'-phosphate (PLP).

[0043] In one embodiment, the isolated probiotic has the ability to increase the bioavailability of agmatine produced from arginine in the gastrointestinal tract of a subject by delaying the conversion of agmatine to downstream polyamines for at least 24 hours.

[0044] In one embodiment, the isolated probiotic has the ability to produce at least 20 μM agmatine from arginine after 24 hours in the gastrointestinal tract of a subject using arginine decarboxylase (ADC) and local microbiota.

[0045] In one embodiment, the isolated probiotic has the ability to survive in a pH 1.5 environment for at least 10 minutes.

[0046] In one embodiment, the isolated probiotic has the ability to survive in a pH 3.5 environment for at least 60 minutes.

[0047] In one embodiment, the gastrointestinal tract of the subject is the lower gastrointestinal tract of the subject.

[0048] In one embodiment, the gastrointestinal tract of the subject is the large intestine of the subject.

[0049] In one embodiment, the isolated probiotic is active.

[0050] In one aspect the present disclosure provides an isolated probiotic for improving pain relief, anti-aging effects, neuroprotective and antidepressant effects, improved vasodilation and metabolic health, improved cellular health, and lifespan, and reducing age-related memory loss in a subject in need thereof by increasing the production of agmatine in the gastrointestinal tract of the subject using a local microbiota. The isolated probiotic has the ability to colonize and survive in the gastrointestinal tract of the subject and produces at least 20 μM agmatine from arginine after 24 hours in the gastrointestinal tract of the subject having a pH range of about 4 to about 8 using arginine decarboxylase (ADC) and a local microbiota in the presence of arginine.

[0051] In one aspect, the present disclosure provides a method for improving pain relief, anti-aging effects, neuroprotective and antidepressant effects, improved vasodilation and metabolic health, improved cellular health, and lifespan, and reducing age-related memory loss in a subject in need thereof by increasing the production of agmatine in the gastrointestinal tract of the subject using a local microbiota. The method includes administering a composition to the subject, the composition comprising: an isolated probiotic; and arginine, wherein the isolated probiotic has the ability to colonize and survive in the gastrointestinal tract of the subject, and produces at least 20 μM agmatine from arginine in the gastrointestinal tract of the subject having a pH range of about 5 to about 8 using arginine decarboxylase (ADC) and a local microbiota 24 hours after administering the composition to the subject.

[0052] In one aspect, the present disclosure provides a composition for improving pain relief, anti-aging effects, neuroprotective and antidepressant effects, improved vasodilation and metabolic health, improved cellular health, and lifespan, and reducing age-related memory loss in a subject in need thereof by increasing the production of agmatine in the gastrointestinal tract of the subject using a local microbiota. The composition comprises: an isolated probiotic; and arginine, wherein the isolated probiotic has the ability to colonize and survive in the gastrointestinal tract of the subject, and produces at least 20 μM agmatine from arginine in the gastrointestinal tract of the subject having a pH range of about 5 to about 8 during 24 hours after administration of the composition to the subject using arginine decarboxylase (ADC) and a local microbiota.

[0053] In one embodiment, the subject can be a mammal, preferably a human, including adults and children. In one embodiment, the isolated probiotic is capable of colonizing and surviving in the gastrointestinal tract of the subject and is capable of converting arginine into agmatine in the gastrointestinal tract of the subject. In one embodiment, the composition comprises probiotics and arginine.

[0054] In one aspect, the present disclosure provides an isolated probiotic capable of colonizing and surviving in the gastrointestinal tract of a subject, the isolated probiotic capable of producing agmatine in the gastrointestinal tract of the subject using a microbiota. In one embodiment, the isolated probiotic is capable of producing agmatine from arginine in the gastrointestinal tract or lower gastrointestinal tract of a subject.

[0055] In one embodiment, the probiotic bacteria separated are bacterial strains that can colonize and survive in the gastrointestinal tract of a subject and can convert arginine into agmatine and / or polyamines (such as putrescine, spermidine and spermine) in the gastrointestinal tract of a subject. In one embodiment, the probiotic bacteria separated are bacterial strains that can convert arginine into agmatine and / or polyamines (such as putrescine, spermidine and spermine) using arginine decarboxylase (ADC). In one embodiment, the probiotic bacteria separated are bacterial strains that can convert arginine into agmatine and / or polyamines (such as putrescine, spermidine and spermine) using ornithine decarboxylase (ODC).

[0056] In one embodiment, the probiotics of separation are bacterial strains that can colonize and survive in the gastrointestinal tract of a subject. In one embodiment, the probiotics of separation are bacterial strains that can convert arginine into agmatine in the gastrointestinal tract of a subject. In one embodiment, the probiotics of separation are bacterial strains that can use arginine decarboxylase (ADC) to convert arginine into agmatine. In one embodiment, the probiotics of separation are bacterial strains that can promote the production of arginine decarboxylase (ADC) in the gastrointestinal tract of a subject and use ADC to convert arginine into agmatine.

[0057] In one embodiment, the probiotic bacteria of separation is lactobacillus acidophilus. In one embodiment, lactobacillus acidophilus can use arginine decarboxylase (ADC) to convert arginine into agmatine. In one embodiment, lactobacillus acidophilus is a strain comprising endogenous enzyme arginine decarboxylase (ADC). In one embodiment, the probiotic bacteria of separation is a lactobacillus acidophilus strain selected from lactobacillus acidophilus NCC 2628 (CNCM I-2453), lactobacillus acidophilus NCC 2766 (CNCM I-3848), lactobacillus acidophilus NCC 2775 (CNCM I-3851), lactobacillus acidophilus NCC 2619 (ATCC 700396).

[0058] In one embodiment, the isolated probiotic is a bacterial strain having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.5% or 99.9% sequence identity to one of Lactobacillus acidophilus NCC 2628 (CNCM I-2453), Lactobacillus acidophilus NCC 2766 (CNCM I-3848), Lactobacillus acidophilus NCC 2775 (CNCM I-3851), Lactobacillus acidophilus NCC2619 (ATCC 700396).

[0059] In one embodiment, the isolated probiotic is a Lactobacillus acidophilus strain having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.5% sequence identity to one of Lactobacillus acidophilus NCC 2628 (CNCM I-2453), Lactobacillus acidophilus NCC 2766 (CNCM I-3848), Lactobacillus acidophilus NCC 2775 (CNCM I-3851), Lactobacillus acidophilus NCC2619 (ATCC 700396).

[0060] In one embodiment, the isolated probiotic is capable of converting arginine to agmatine in the gastrointestinal tract of a subject at a pH of at least about 4.0, at least about 5.0, at least about 6.0, between about 5.0 and about 9.0, between about 6.0 and about 8.0, or about 7.0.

[0061] In one embodiment, the isolated probiotic is capable of converting arginine to agmatine in the gastrointestinal tract of a subject.

[0062] In one embodiment, the isolated probiotic is capable of converting arginine to agmatine in the gastrointestinal tract of a subject to achieve an agmatine concentration of at least 5 μM, at least 10 μM, at least 20 μM, at least 30 μM, at least 40 μM, at least 50 μM, at least 60 μM, at least 70 μM, at least 80 μM, at least 90 μM, at least 95 μM, at least 100 μM, at least 105 μM, at least 110 μM, at least 115 μM, at least 120 μM, at least 125 μM, at least 130 μM, at least 200 μM; at least 300 μM, at least 400 μM, at least 500 μM; at least 600 μM, at least 700 μM or at least 800 μM 24 hours after administration of the composition.

[0063] In one embodiment, the isolated probiotic is able to survive in the stomach acid environment of a subject for at least 5 minutes, at least 10 minutes, at least 20 minutes, at least 30 minutes, at least 40 minutes, at least 50 minutes, at least 60 minutes, or at least 70 minutes.

[0064] In one embodiment, the isolated probiotic bacteria is able to survive in a pH 2.6 environment for at least 10 minutes, at least 20 minutes, at least 30 minutes, at least 40 minutes, at least 50 minutes, at least 60 minutes, or at least 70 minutes.

[0065] In one embodiment, the isolated probiotic bacteria is able to survive in a pH 3.4 environment for at least 60 minutes.

[0066] In one embodiment, the subject is a human. The gastric acid in the human stomach has a pH of about 1.5 to 3.5. The isolated probiotic bacteria are able to survive in the gastric acid environment of the human stomach.

[0067] In one aspect, the present disclosure provides compositions for increasing the production of agmatine and / or polyamines in a body part of a subject using a microbiota so as to provide certain health benefits to the subject, such as pain relief, anti-aging effects, neuroprotective and anti-depressant effects, improved vasodilation and metabolic health, improved cellular health, and longevity.

[0068] In one embodiment, the present disclosure provides a composition for improving pain relief, anti-aging effects, neuroprotective and antidepressant effects, vasodilation and metabolic health, cell health and life span in a subject in need thereof. The composition comprises a microorganism or bacteria. In one embodiment, the microorganism is a probiotic. In one embodiment, the isolated probiotic can increase the production of agmatine and / or polyamines in a body part of a subject. In one embodiment, the isolated probiotic can colonize and survive in the gastrointestinal tract of a subject.

[0069] In one embodiment, the subject's body part is the subject's gastrointestinal tract, lower gastrointestinal tract, intestine, small intestine or large intestine. In one embodiment, the production of agmatine and / or polyamines is at the subject's gastrointestinal tract. In one embodiment, the production of agmatine is at the subject's lower gastrointestinal tract. In one embodiment, the production of agmatine is at the subject's small intestine.

[0070] In one embodiment, the production of agmatine is in the large intestine of the subject.In one embodiment, the isolated probiotic is capable of colonizing and surviving in the gastrointestinal tract of the subject and is also capable of increasing the production of agmatine in the gastrointestinal tract of the subject.

[0071] In one embodiment, compositions also comprises arginine.In one embodiment, the probiotic bacteria of separation is the bacterial strain that can convert arginine into agmatine and / or polyamines (such as putrescine, spermidine and spermine) in the gastrointestinal tract of experimenter.In one embodiment, the probiotic bacteria of separation is the bacterial strain that can use arginine decarboxylase (ADC) to convert arginine into agmatine and / or polyamines (such as putrescine, spermidine and spermine).In one embodiment, the probiotic bacteria of separation is the bacterial strain that can use ornithine decarboxylase (ODC) to convert arginine into agmatine and / or polyamines (such as putrescine, spermidine and spermine).In one embodiment, the probiotic bacteria of separation is the bacterial strain that can promote the generation of arginine decarboxylase (ADC) in the gastrointestinal tract of experimenter and use ADC to convert arginine into agmatine.

[0072] In one embodiment, the probiotic isolated is Lactobacillus acidophilus. In one embodiment, the composition comprises Lactobacillus acidophilus and arginine. In one embodiment, Lactobacillus acidophilus can convert arginine into agmatine and / or other polyamines (such as putrescine, spermidine and spermine) using arginine decarboxylase (ADC). In one embodiment, Lactobacillus acidophilus is a strain comprising an endogenous enzyme arginine decarboxylase (ADC).

[0073] In one embodiment, the isolated probiotic is a Lactobacillus acidophilus strain selected from Lactobacillus acidophilus NCC 2628 (CNCM 1-2453), Lactobacillus acidophilus NCC 2766 (CNCM 1-3848), Lactobacillus acidophilus NCC 2775 (CNCM 1-3851), Lactobacillus acidophilus NCC2619 (ATCC 700396) and combinations thereof.

[0074] In one embodiment, the isolated probiotic is a bacterial strain having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.5% or 99.9% sequence identity to one or more of Lactobacillus acidophilus NCC 2628 (CNCM I-2453), Lactobacillus acidophilus NCC 2766 (CNCM I-3848), Lactobacillus acidophilus NCC 2775 (CNCM I-3851), and Lactobacillus acidophilus NCC2619 (ATCC 700396).

[0075] In one embodiment, the isolated probiotic is a Lactobacillus acidophilus strain having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.5% sequence identity to one or more of Lactobacillus acidophilus NCC 2628 (CNCM I-2453), Lactobacillus acidophilus NCC 2766 (CNCM I-3848), Lactobacillus acidophilus NCC 2775 (CNCM I-3851), and Lactobacillus acidophilus NCC2619 (ATCC 700396).

[0076] The concentration of agmatine produced from arginine in the gastrointestinal tract of the subject depends on the subject. In one embodiment, the concentration of agmatine in the gastrointestinal tract of the subject is at least 5 μM, at least 10 μM, at least 20 μM, at least 30 μM, at least 40 μM, at least 50 μM, at least 60 μM, at least 70 μM, at least 80 μM, at least 90 μM, at least 95 μM, at least 100 μM, at least 105 μM, at least 110 μM, at least 115 μM, at least 120 μM, at least 125 μM, at least 130 μM, at least 200 μM; at least 300 μM, at least 400 μM, at least 500 μM; at least 600 μM, at least 700 μM or at least 800 μM 24 hours after administration of the composition.

[0077] In one embodiment, the composition further comprises one or more of a starch source, a protein source, and a lipid source.

[0078] Suitable starch sources are, for example, cereals and legumes, such as corn, rice, wheat, barley, oats, soy beans and mixtures thereof.

[0079] Suitable protein sources may be selected from any suitable animal or vegetable protein source, for example meat and meal, poultry meat or meal, fish meat or meal, soy protein concentrate, dairy protein, gluten and the like.

[0080] Suitable lipid sources include meat, animal fats and vegetable oils or fats.

[0081] The choice of starch, protein, and lipid sources will be determined primarily by the nutritional needs of the subject, palatability considerations, and the type of product being administered.

[0082] Furthermore, various other ingredients such as sugar, salt, spices, seasonings, vitamins, minerals, flavoring agents, fats, etc. may be incorporated into the composition as desired.

[0083] In one embodiment, the composition is in the form of a dry powder, a capsule, a shelf-stable liquid, or a wet, frozen or shelf-stable paste. In one embodiment, the composition is a powder. In one embodiment, the composition is in the form of a capsule. In one embodiment, the composition is a dry powder and the isolated probiotic bacteria are coated on or filled into the composition.

[0084] In one embodiment, the isolated probiotic bacteria are active in the final composition.

[0085] In one embodiment, the isolated probiotic is able to survive in the stomach acid environment of a subject for at least 10 minutes, at least 20 minutes, at least 30 minutes, at least 40 minutes, at least 50 minutes, at least 60 minutes, or at least 70 minutes.

[0086] In one embodiment, the isolated probiotic bacteria is able to survive in a pH 2.6 environment for at least 10 minutes.

[0087] In one embodiment, the isolated probiotic bacteria is able to survive in a pH 3.4 environment for at least 60 minutes.

[0088] In one embodiment, the subject is a human. The gastric acid in the human stomach has a pH of about 1.5 to 3.5. The isolated probiotics can survive in the gastric acid environment of the human stomach for at least 10 minutes, at least 20 minutes, at least 30 minutes, at least 40 minutes, at least 50 minutes, at least 60 minutes, or at least 70 minutes.

[0089] In one embodiment, the composition is in the form of a capsule. In one embodiment, the isolated probiotic bacteria can survive in the acid environment of the human stomach for at least 10 minutes, at least 20 minutes, at least 30 minutes, at least 40 minutes, at least 50 minutes, at least 60 minutes, or at least 70 minutes.

[0090] In one embodiment, the capsule enables the isolated probiotic bacteria to survive in the acid environment of a human stomach for at least 0 minutes, at least 20 minutes, at least 30 minutes, at least 40 minutes, at least 50 minutes, at least 60 minutes, at least 70 minutes, at least 80 minutes, at least 90 minutes, at least 100 minutes, at least 110 minutes, at least 2 hours, at least 3 hours, or at least 4 hours.

[0091] In one aspect, the present disclosure provides a method for increasing the production of agmatine and / or polyamines in a body part of a subject using a microbiota to provide certain health benefits to the subject, such as pain relief, anti-aging effects, neuroprotective and anti-depressant effects, improved vasodilation and metabolic health, improved cellular health and longevity. The method comprises administering a composition to the subject.

[0092] In one aspect, the present disclosure provides a method for improving pain relief, anti-aging effects, neuroprotective and anti-depressant effects, improved vasodilation and metabolic health, improved cellular health, and longevity in a subject in need thereof by increasing the production of agmatine and / or polyamines in a body part of a subject using a microbiota, the method comprising administering to the subject a composition discussed above and elsewhere in the present disclosure.

[0093] In one embodiment, the method further comprises administering to the subject an effective amount of the composition to provide at least 500 mg to 700 mg of arginine per day and / or at least 5 million CFU-7 million CFU of the isolated probiotic per day for at least 1 month, at least 3 months, or at least 6 months.

[0094] In one embodiment, the method further comprises administering the composition in an amount effective to provide the subject with a daily dose of the isolated probiotic in an amount of at least 7 million CFU and a daily dose of arginine in an amount of at least 3 g / L of the composition.

[0095] In one embodiment, the composition comprises a probiotic capable of colonizing and surviving in the gastrointestinal tract of a subject and further capable of increasing the production of agmatine in the gastrointestinal tract of the subject.

[0096] In one embodiment, the composition further comprises arginine.

[0097] In one embodiment, the body part of the subject is the gastrointestinal tract of the subject. In one embodiment, the production of agmatine and / or polyamines is at the gastrointestinal tract of the subject. In one embodiment, the production of agmatine is at the lower gastrointestinal tract of the subject. In one embodiment, the production of agmatine is at the lower gastrointestinal tract of the subject. In one embodiment, the production of agmatine is at the small intestine of the subject. In one embodiment, the production of agmatine is at the large intestine of the subject.

[0098] In one embodiment, the probiotic bacteria of separation is a bacterial strain that can convert arginine into agmatine and / or polyamines (such as putrescine, spermidine and spermine) in the gastrointestinal tract of the experimenter. In one embodiment, the probiotic bacteria of separation is a bacterial strain that can use arginine decarboxylase (ADC) to convert arginine into agmatine and / or polyamines (such as putrescine, spermidine and spermine). In one embodiment, the probiotic bacteria of separation is a bacterial strain that can use ornithine decarboxylase (ODC) to convert arginine into agmatine and / or polyamines (such as putrescine, spermidine and spermine). In one embodiment, the probiotic bacteria of separation is a bacterial strain that can promote the generation of arginine decarboxylase (ADC) in the gastrointestinal tract of the experimenter and use ADC to convert arginine into agmatine.

[0099] In one embodiment, the probiotic isolated is Lactobacillus acidophilus. In one embodiment, the composition comprises Lactobacillus acidophilus and arginine. In one embodiment, Lactobacillus acidophilus can convert arginine into agmatine and / or other polyamines (such as putrescine, spermidine and spermine) using arginine decarboxylase (ADC). In one embodiment, Lactobacillus acidophilus is a strain comprising an endogenous enzyme arginine decarboxylase (ADC).

[0100] In one embodiment, the isolated probiotic is a Lactobacillus acidophilus strain selected from Lactobacillus acidophilus NCC 2628 (CNCM 1-2453), Lactobacillus acidophilus NCC 2766 (CNCM 1-3848), Lactobacillus acidophilus NCC 2775 (CNCM 1-3851), Lactobacillus acidophilus NCC2619 (ATCC 700396) and combinations thereof.

[0101] In one embodiment, the isolated probiotic bacterium is Lactobacillus acidophilus.

[0102] In one embodiment, the isolated probiotic is a bacterial strain having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.5% or 99.9% sequence identity to one or more of Lactobacillus acidophilus NCC 2628 (CNCM I-2453), Lactobacillus acidophilus NCC 2766 (CNCM I-3848), Lactobacillus acidophilus NCC 2775 (CNCM I-3851), and Lactobacillus acidophilus NCC2619 (ATCC 700396).

[0103] In one embodiment, the isolated probiotic is a Lactobacillus acidophilus strain having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.5% sequence identity to one or more of Lactobacillus acidophilus NCC 2628 (CNCM I-2453), Lactobacillus acidophilus NCC 2766 (CNCM I-3848), Lactobacillus acidophilus NCC 2775 (CNCM I-3851), and Lactobacillus acidophilus NCC2619 (ATCC 700396).

[0104] In one embodiment, the composition is in the form of a dry powder, capsule, shelf-stable liquid, or a wet, frozen or shelf-stable paste. In one embodiment, the composition is a powder. In one embodiment, the composition is in the form of a capsule. In one embodiment, the composition is a dry powder and the isolated probiotic bacteria are coated on the composition or filled into the composition. In one embodiment, the isolated probiotic bacteria are active in the composition.

[0105] In one embodiment, the concentration of agmatine in the gastrointestinal tract of a subject about 24 hours after administration of the composition is at least 5 μM, at least 10 μM, at least 20 μM, at least 30 μM, at least 40 μM, at least 50 μM, at least 60 μM, at least 70 μM, at least 80 μM, at least 90 μM, at least 95 μM, at least 100 μM, at least 105 μM, at least 110 μM, at least 115 μM, at least 120 μM, at least 125 μM, or at least 130 μM.

[0106] In one embodiment, the isolated probiotic is able to survive in the stomach acid environment of a subject for at least 10 minutes, at least 20 minutes, at least 30 minutes, at least 40 minutes, at least 50 minutes, at least 60 minutes, or at least 70 minutes.

[0107] In one embodiment, the isolated probiotic bacteria is able to survive in a pH 2.6 environment for at least 10 minutes.

[0108] In one embodiment, the isolated probiotic bacteria is able to survive in a pH 3.4 environment for at least 60 minutes.

[0109] In one embodiment, the subject can be a mammal, preferably a human, including adults and children. BRIEF DESCRIPTION OF THE DRAWINGS

[0110] Figure 1 Substrates and enzymes involved in agmatine homeostasis are shown

[34] .

[0111] Figure 2 The contents of the polyamines agmatine (AGM), putrescine (PUT), cadaverine (CAD), spermidine (SPD), and spermine (SPM) in seeds, sprouts, and shoots of alfalfa are shown

[36] .

[0112] Figure 3 The metabolism and transport of polyamines in mammalian cells and microbiota are shown.

[0113] Figure 4 A hybrid mechanism of the putrescine production pathway was shown, consisting of cooperation between bacteria with an acid-tolerant system and bacteria with an ATP synthesis system

[19] .

[0114] Figure 5 Shown are test results of the effect of agmatine production using a combination of arginine and FOS investigated in the experiments of Example 1 disclosed herein.

[0115] Figure 6 The graph shows the test results of the evolution of agmatine concentration over time (T5h, T24h, T48h) using the strain screening in the experimental study in Example 2 disclosed herein.

[0116] Figure 7 Shown are test results for the effect of test tube and batch fermentation on agmatine concentration from the experimental study in Example 3 disclosed herein.

[0117] Fig. 8A and Figure 8B The test results of the effect of strains with various donors on agmatine production are shown: A represents the total ratio, B represents the scale-up ratio from 0 μM to 50 μM of the experimental study in Example 4 disclosed herein.

[0118] Fig. 9 Shown are test results of the effect of different pH conditions on agmatine concentration for the experimental study in Example 5 disclosed herein.

[0119] Fig.10 and Fig.11 Shown are the results of testing the effects of various specific strains incubated with Donor 1 on the concentration of agmatine investigated in the experiments in Example 6 disclosed herein.

[0120] Fig.12 Shown are the test results of the experimental study in Example 7 disclosed herein for the effect of four different strains of Lactobacillus acidophilus on the concentration and bioavailability of agmatine using in vitro fermentation of arginine. DETAILED DESCRIPTION

[0121] definition

[0122] Some definitions are provided below. However, definitions may be located in the "Implementation" section below, and the above heading "Definitions" does not indicate that such disclosure in the "Implementation" section is not a definition.

[0123] As used in this disclosure and the appended claims, the term "intestinal tract" refers to the organs, glands, ducts, and systems responsible for the transfer and digestion of food, the absorption of nutrients, and the excretion of waste. In humans, the intestinal tract includes the gastrointestinal tract. The intestinal tract also includes accessory organs and glands, such as the spleen, liver, gallbladder, and pancreas. Bacteria can be found throughout the intestinal tract, for example, in the gastrointestinal tract, particularly in the intestine.

[0124] As used in this disclosure and the appended claims, the term "gastrointestinal tract" (also referred to as the GI tract, GIT, digestive tract, digestion tract, or alimentary canal) refers to the tract from the mouth to the anus, which includes all organs of the digestive system of humans and other animals. Food ingested through the mouth is digested to extract nutrients and absorb energy, and waste is excreted as feces. The gastrointestinal tract includes the mouth, esophagus, stomach, small intestine, and large intestine. The human gastrointestinal tract includes the mouth, esophagus, stomach, and intestines, and is divided into the upper gastrointestinal tract and the lower gastrointestinal tract. The GI tract includes all structures between the mouth and the anus, forming a continuous passage including the major organs of digestion (i.e., the stomach, small intestine, and large intestine). However, the complete human digestive system consists of the gastrointestinal tract plus the accessory organs of digestion (tongue, salivary glands, pancreas, liver, and gallbladder).

[0125] As used in this disclosure and the appended claims, the term "upper gastrointestinal tract" refers to the gastrointestinal tract including the oral cavity, pharynx, esophagus, stomach, and duodenum of the small intestine.

[0126] As used in this disclosure and the appended claims, the term "lower gastrointestinal tract" refers to the gastrointestinal tract including the remainder of the small intestine (i.e., the jejunum and ileum) and all of the large intestine (i.e., the cecum, colon, rectum, and anal canal). Bacteria can be found in the gastrointestinal tract, particularly in the intestine.

[0127] As used in this disclosure and the appended claims, the term "non-pathogenic bacteria" refers to bacteria that are incapable of causing disease or adverse reactions in a host. In one embodiment, the non-pathogenic bacteria are commensal bacteria. Examples of non-pathogenic bacteria include, but are not limited to, Bacillus, Bacteroides, Bifidobacterium, Brevibacteria, Clostridium, Escherichia coli, Lactobacillus (such as Lactobacillus acidophilus, Lactobacillus bulgaricus, Lactobacillus casei, Lactobacillus johnsonii, Lactobacillus paracasei, Lactobacillus plantarum, Lactobacillus reuteri, Lactobacillus rhamnosus), Lactococcus, Saccharomyces, and Staphylococcus. Natural pathogenic bacteria can be genetically engineered to reduce or eliminate pathogenicity. A particular bacterial strain may be non-pathogenic in one species but pathogenic in another species. A bacterial species may have many different types or strains. One strain of a bacterial species may be non-pathogenic and another strain of the same bacteria may be pathogenic.

[0128] As used in the present disclosure and the appended claims, the term "probiotic" refers to live non-pathogenic microorganisms, such as bacteria, which can confer health benefits to host organisms containing appropriate amounts of microorganisms, usually by improving or restoring intestinal flora or microbiota. In some embodiments, the host organism is a mammal. In some embodiments, the host organism is a human. Some species, strains and / or subtypes of non-pathogenic bacteria are currently considered to be probiotic bacteria. Examples of probiotic bacteria include, but are not limited to, Bifidobacterium, Escherichia coli, Lactobacillus acidophilus, Lactobacillus bulgaricus, Lactobacillus paracasei, Lactobacillus plantarum and Saccharomyces boulardii. The isolated probiotic can be a variant or mutant strain of bacteria. Non-pathogenic bacteria can be genetically engineered to enhance or improve desired biological properties, such as, viability. Non-pathogenic bacteria can be genetically engineered to provide probiotic properties. Probiotics can be genetically engineered to enhance or improve probiotic properties.

[0129] As used in this disclosure and the appended claims, the term "composition" refers to a preparation of the probiotic bacteria of the present invention with other components such as fats, proteins, starches, flavoring agents, vitamins, prebiotics, cellulose derivatives, gelatin, surfactants, polyethylene glycol, calcium bicarbonate, calcium phosphate and dietary fiber.

[0130] All percentages expressed herein are by weight based on the total weight of the composition unless otherwise indicated.When reference is made herein to pH, the value corresponds to the pH measured at about 25°C using standard equipment.

[0131] As used herein, "about", "approximately" and "substantially" should be understood to refer to a number within a certain numerical range, for example, within the range of -10% to +10% of the mentioned number, preferably -5% to +5% of the mentioned number, more preferably -1% to +1% of the mentioned number, and most preferably -0.1% to +0.1% of the mentioned number.

[0132] All numerical ranges herein should be understood to include all integers or fractions within the range. In addition, these numerical ranges should be understood to provide support for claims involving any number or subset of numbers within the range. For example, the disclosure of 1 to 10 should be understood to support ranges of 1 to 8, 3 to 7, 1 to 9, 3.6 to 4.6, 3.5 to 9.9, etc.

[0133] As used in this disclosure and the appended claims, the singular forms "a," "an," and "the" include plural referents unless the context clearly dictates otherwise. Thus, for example, reference to "a component" or "the component" includes two or more components.

[0134] The words "include / comprising" will all be interpreted as inclusive rather than exclusive. Likewise, the terms "include", "including", "containing" and "having" will all be considered inclusive unless the context clearly prohibits such an interpretation. Furthermore, in this regard, these terms specify the presence of stated features but do not exclude the presence of additional or other features.

[0135] However, the compositions and methods disclosed herein may be free of any elements not expressly disclosed herein. Thus, disclosures of embodiments using the term "comprising" are disclosures of (i) embodiments having the identified components or steps and additional components or steps, (ii) embodiments "consisting essentially of" the identified components or steps, and (iii) embodiments "consisting of" the identified components or steps. Any embodiment disclosed herein may be combined with any other embodiment disclosed herein.

[0136] The term "and / or" used in the context of "X and / or Y" should be interpreted as "X" or "Y" or "X and Y". Similarly, "at least one of X or Y" should be interpreted as "X" or "Y" or "X and Y". For example, "at least one of monosodium phosphate or disodium phosphate" should be interpreted as "monosodium phosphate" or "disodium phosphate" or "both monosodium phosphate and disodium phosphate".

[0137] As used herein, the terms "example" and "such as" (especially when followed by a list of terms) are exemplary and illustrative only and should not be considered exclusive or comprehensive.

[0138] A "subject" or "individual" or "host organism" is a mammal, preferably a human. As used herein, an "effective amount" is an amount that prevents a defect, treats a disease or medical condition in an individual, or more generally, reduces symptoms, manages the progression of a disease, or provides a nutritional, physiological or medical benefit to the individual.

[0139] The term "treatment" includes both preventive or preventive treatment (preventing and / or delaying the development of target pathological conditions or disorders), as well as curative, therapeutic or disease-modifying treatments, including therapeutic measures to cure, delay, alleviate symptoms of confirmed pathological conditions or disorders and / or interrupt their progression; and treat patients who are at risk of contracting a disease or suspected of contracting a disease, as well as treat patients who are ill or have been diagnosed with a disease or medical condition. The term "treatment" does not necessarily mean that the subject is treated until full recovery. The term "treatment" also refers to health maintenance and / or promotion in individuals who do not suffer from the disease but may be prone to developing unhealthy conditions. The term "treatment" is also intended to include strengthening or otherwise enhancing one or more major preventive or therapeutic measures. As a non-limiting example, treatment can be performed by a patient, a caregiver, a doctor, a nurse, or another healthcare professional.

[0140] As used herein, the term "unit dosage form" refers to physically discrete units suitable as unit dosages for human and animal subjects, each unit containing a predetermined amount of the composition disclosed herein in association with a pharmaceutically acceptable diluent, carrier or vehicle, an amount sufficient to produce the desired effect. The specifications for the unit dosage form depend on the specific compound used, the effect to be achieved, and the pharmacodynamics associated with each compound in the host.

[0141] As used herein, the term "mM" refers to the molar concentration unit of an aqueous solution, which is mmol / L. For example, 1.0 mM is equal to 1.0 mmol / L. As used herein, the term "μM" refers to the molar concentration unit of an aqueous solution, which is μmol / L. For example, 1.0 μM is equal to 1.0 μmol / L.

[0142] The terms "substantially free," "essentially free," or "substantially free" when used in reference to a particular component mean that any component present constitutes less than about 3.0 weight percent, such as less than about 2.0 weight percent, less than about 1.0 weight percent, preferably less than about 0.5 weight percent, or more preferably less than about 0.1 weight percent.

[0143] Implementation

[0144] The present disclosure generally relates to probiotics, compositions and methods for producing agmatine using a microbial population, and more specifically, to probiotics, compositions and methods for increasing the production of agmatine and / or polyamines in the gastrointestinal tract of a subject so as to provide certain health benefits (such as pain relief, anti-aging effects, neuroprotection and antidepressant effects, improved vasodilation and metabolic health, improved cell health and life span) to the subject. In one embodiment, the subject can be a mammal, preferably a human, including adults and children. In one embodiment, the isolated probiotics can colonize and survive in the gastrointestinal tract of the subject and can convert arginine into agmatine in the gastrointestinal tract of the subject. In one embodiment, the composition comprises probiotics and arginine.

[0145] In one aspect, the present disclosure provides probiotics capable of colonizing and surviving in the gastrointestinal tract of a subject, the isolated probiotics capable of producing agmatine in the gastrointestinal tract of the subject using a microbiota. In one embodiment, the isolated probiotics are capable of producing agmatine from arginine in the gastrointestinal tract or lower gastrointestinal tract of a subject.

[0146] In one embodiment, the probiotic bacteria separated are bacterial strains that can colonize and survive in the gastrointestinal tract of a subject and can convert arginine into agmatine and / or polyamines (such as putrescine, spermidine and spermine) in the gastrointestinal tract of a subject. In one embodiment, the probiotic bacteria separated are bacterial strains that can convert arginine into agmatine and / or polyamines (such as putrescine, spermidine and spermine) using arginine decarboxylase (ADC). In one embodiment, the probiotic bacteria separated are bacterial strains that can convert arginine into agmatine and / or polyamines (such as putrescine, spermidine and spermine) using ornithine decarboxylase (ODC).

[0147] In one embodiment, the probiotics of separation are bacterial strains that can colonize and survive in the gastrointestinal tract of a subject. In one embodiment, the probiotics of separation are bacterial strains that can convert arginine into agmatine in the gastrointestinal tract of a subject. In one embodiment, the probiotics of separation are bacterial strains that can use arginine decarboxylase (ADC) to convert arginine into agmatine. In one embodiment, the probiotics of separation are bacterial strains that can promote the production of arginine decarboxylase (ADC) in the gastrointestinal tract of a subject and use ADC to convert arginine into agmatine.

[0148] In one embodiment, the probiotic bacteria of separation is lactobacillus acidophilus. In one embodiment, lactobacillus acidophilus can use arginine decarboxylase (ADC) to convert arginine into agmatine. In one embodiment, lactobacillus acidophilus is a strain comprising endogenous enzyme arginine decarboxylase (ADC). In one embodiment, the probiotic bacteria of separation is a lactobacillus acidophilus strain selected from lactobacillus acidophilus NCC 2628 (CNCM I-2453), lactobacillus acidophilus NCC 2766 (CNCM I-3848), lactobacillus acidophilus NCC 2775 (CNCM I-3851), lactobacillus acidophilus NCC 2619 (ATCC 700396).

[0149] In one embodiment, the isolated probiotic is a bacterial strain having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.5% or 99.9% sequence identity to one of Lactobacillus acidophilus NCC 2628 (CNCM I-2453), Lactobacillus acidophilus NCC 2766 (CNCM I-3848), Lactobacillus acidophilus NCC 2775 (CNCM I-3851), Lactobacillus acidophilus NCC2619 (ATCC 700396).

[0150] In one embodiment, the isolated probiotic is a Lactobacillus acidophilus strain having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.5% sequence identity to one of Lactobacillus acidophilus NCC 2628 (CNCM I-2453), Lactobacillus acidophilus NCC 2766 (CNCM I-3848), Lactobacillus acidophilus NCC 2775 (CNCM I-3851), Lactobacillus acidophilus NCC2619 (ATCC 700396).

[0151] In one embodiment, the isolated probiotic is capable of converting arginine to agmatine in the gastrointestinal tract of a subject at a pH of at least about 4.0, at least about 5.0, at least about 6.0, between about 5.0 and about 9.0, between about 6.0 and about 8.0, or about 7.0.

[0152] In one embodiment, the isolated probiotic is capable of converting arginine to agmatine in the gastrointestinal tract of a subject in the presence of a prebiotic such as fructooligosaccharides (FOS).

[0153] In one embodiment, the isolated probiotic is capable of converting arginine to agmatine in the gastrointestinal tract of a subject to achieve an agmatine concentration of at least 5 μM, at least 10 μM, at least 20 μM, at least 30 μM, at least 40 μM, at least 50 μM, at least 60 μM, at least 70 μM, at least 80 μM, at least 90 μM, at least 95 μM, at least 100 μM, at least 105 μM, at least 110 μM, at least 115 μM, at least 120 μM, at least 125 μM, at least 130 μM, at least 200 μM; at least 300 μM, at least 400 μM, at least 500 μM; at least 600 μM, at least 700 μM or at least 800 μM 24 hours after administration of the composition.

[0154] In one aspect, the present disclosure provides compositions for increasing the production of agmatine and / or polyamines in a body part of a subject using a microbiota so as to provide certain health benefits to the subject, such as pain relief, anti-aging effects, neuroprotective and anti-depressant effects, improved vasodilation and metabolic health, improved cellular health, and longevity.

[0155] In one embodiment, the present disclosure provides a composition for improving pain relief, anti-aging effects, neuroprotective and antidepressant effects, vasodilation and metabolic health, cell health and life span in a subject in need thereof. The composition comprises a microorganism or bacteria. In one embodiment, the microorganism is a probiotic. In one embodiment, the isolated probiotic can increase the production of agmatine and / or polyamines in a body part of a subject. In one embodiment, the isolated probiotic can colonize and survive in the gastrointestinal tract of a subject.

[0156] In one embodiment, the subject's body part is the subject's gastrointestinal tract, lower gastrointestinal tract, intestine, small intestine or large intestine. In one embodiment, the production of agmatine and / or polyamines is at the subject's gastrointestinal tract. In one embodiment, the production of agmatine is at the subject's lower gastrointestinal tract. In one embodiment, the production of agmatine is at the subject's small intestine.

[0157] In one embodiment, the production of agmatine is in the large intestine of the subject.In one embodiment, the isolated probiotic is capable of colonizing and surviving in the gastrointestinal tract of the subject and is also capable of increasing the production of agmatine in the gastrointestinal tract of the subject.

[0158] In one embodiment, compositions also comprises arginine.In one embodiment, the probiotic bacteria of separation is the bacterial strain that can convert arginine into agmatine and / or polyamines (such as putrescine, spermidine and spermine) in the gastrointestinal tract of experimenter.In one embodiment, the probiotic bacteria of separation is the bacterial strain that can use arginine decarboxylase (ADC) to convert arginine into agmatine and / or polyamines (such as putrescine, spermidine and spermine).In one embodiment, the probiotic bacteria of separation is the bacterial strain that can use ornithine decarboxylase (ODC) to convert arginine into agmatine and / or polyamines (such as putrescine, spermidine and spermine).In one embodiment, the probiotic bacteria of separation is the bacterial strain that can promote the generation of arginine decarboxylase (ADC) in the gastrointestinal tract of experimenter and use ADC to convert arginine into agmatine.

[0159] In one embodiment, the probiotic isolated is Lactobacillus acidophilus. In one embodiment, the composition comprises Lactobacillus acidophilus and arginine. In one embodiment, Lactobacillus acidophilus can convert arginine into agmatine and / or other polyamines (such as putrescine, spermidine and spermine) using arginine decarboxylase (ADC). In one embodiment, Lactobacillus acidophilus is a strain comprising an endogenous enzyme arginine decarboxylase (ADC).

[0160] In one embodiment, the isolated probiotic is a Lactobacillus acidophilus strain selected from Lactobacillus acidophilus NCC 2628 (CNCM 1-2453), Lactobacillus acidophilus NCC 2766 (CNCM 1-3848), Lactobacillus acidophilus NCC 2775 (CNCM 1-3851), Lactobacillus acidophilus NCC2619 (ATCC 700396) and combinations thereof.

[0161] In one embodiment, the isolated probiotic is a bacterial strain having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.5% or 99.9% sequence identity to one or more of Lactobacillus acidophilus NCC 2628 (CNCM I-2453), Lactobacillus acidophilus NCC 2766 (CNCM I-3848), Lactobacillus acidophilus NCC 2775 (CNCM I-3851), and Lactobacillus acidophilus NCC2619 (ATCC 700396).

[0162] In one embodiment, the isolated probiotic is a Lactobacillus acidophilus strain having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.5% sequence identity to one or more of Lactobacillus acidophilus NCC 2628 (CNCM I-2453), Lactobacillus acidophilus NCC 2766 (CNCM I-3848), Lactobacillus acidophilus NCC 2775 (CNCM I-3851), and Lactobacillus acidophilus NCC2619 (ATCC 700396).

[0163] In one embodiment, the composition further comprises an acidifying compound. In one embodiment, the acidifying compound is a prebiotic, such as fructooligosaccharides (FOS). In one embodiment, the composition further comprises a prebiotic. In one embodiment, the composition further comprises fructooligosaccharides (FOS).

[0164] In one embodiment, the composition further comprises a cofactor, such as pyridoxal 5'-phosphate (PLP).

[0165] In one embodiment, the concentration of agmatine in the gastrointestinal tract of a subject 24 hours after administration of the composition is at least 5 μM, at least 10 μM, at least 20 μM, at least 30 μM, at least 40 μM, at least 50 μM, at least 60 μM, at least 70 μM, at least 80 μM, at least 90 μM, at least 95 μM, at least 100 μM, at least 105 μM, at least 110 μM, at least 115 μM, at least 120 μM, at least 125 μM, at least 130 μM, at least 200 μM; at least 300 μM, at least 400 μM, at least 500 μM; at least 600 μM, at least 700 μM or at least 800 μM.

[0166] In one embodiment, the composition further comprises one or more of a starch source, a protein source, and a lipid source.

[0167] Suitable starch sources are, for example, cereals and legumes, such as corn, rice, wheat, barley, oats, soy beans and mixtures thereof.

[0168] Suitable protein sources may be selected from any suitable animal or vegetable protein source, for example meat and meal, poultry meat or meal, fish meat or meal, soy protein concentrate, dairy protein, gluten and the like.

[0169] Suitable lipid sources include meat, animal fats and vegetable oils or fats.

[0170] The choice of starch, protein, and lipid sources will be determined primarily by the nutritional needs of the subject, palatability considerations, and the type of product being administered.

[0171] Furthermore, various other ingredients such as sugar, salt, spices, seasonings, vitamins, minerals, flavoring agents, fats, etc. may be incorporated into the composition as desired.

[0172] In one embodiment, the composition is in the form of a dry powder, capsule, shelf-stable liquid, or a wet, frozen or shelf-stable paste. In one embodiment, the composition is a powder. In one embodiment, the composition is in the form of a capsule. In one embodiment, the composition is a dry powder and the separated probiotic bacteria are coated on or filled into the composition. In one embodiment, the separated probiotic bacteria are active in the final composition.

[0173] In one embodiment, the isolated probiotic is able to survive in the stomach acid environment of a subject for at least 10 minutes, at least 20 minutes, at least 30 minutes, at least 40 minutes, at least 50 minutes, at least 60 minutes, or at least 70 minutes.

[0174] In one embodiment, the isolated probiotic bacteria is able to survive in a pH 1.5 environment for at least 10 minutes.

[0175] In one embodiment, the isolated probiotic bacteria is able to survive in a pH 2.6 environment for at least 10 minutes.

[0176] In one embodiment, the isolated probiotic bacteria is able to survive in a pH 3.4 environment for at least 60 minutes.

[0177] In one embodiment, the subject is a human. The gastrointestinal pH profile of a healthy subject is described as follows. The intraluminal pH changes rapidly from the strong acidity in the stomach to about pH 6 in the duodenum. The pH in the small intestine gradually increases from pH 6 to about pH 7.4 in the terminal ileum. The pH in the cecum drops to 5.7, but gradually increases again, reaching pH 6.7 in the rectum. In order for the isolated probiotics to reach the lower gastrointestinal tract to colonize and convert arginine into agmatine, the isolated probiotics need to survive in the highly acidic fluid environment in the stomach by themselves or by being protected in a capsule that can withstand the highly acidic fluid environment in the stomach.

[0178] The normal volume of human gastric fluid is about 20mL to about 100mL, and gastric fluid is strongly acidic, also known as gastric acid. The gastric acid in the human gastric cavity usually has a pH of about 1.5 to 3.5, which is maintained by the proton pump H+ / K+ATPase. The strongly acidic environment in the gastric cavity degrades food including protein. In this process, parietal cells release bicarbonate into the bloodstream, which causes a temporary increase in pH in the blood, called an alkaline tide. When a meal is ingested, gastric pH rises due to the buffering effect of the meal, and then returns to baseline due to the secretion of gastric acid.

[0179] In the present disclosure, the isolated probiotic bacteria are able to survive the acidic environment of the human stomach to reach the small intestine, large intestine or lower gastrointestinal tract where they colonize and convert arginine to agmatine using arginine decarboxylase (ADC) and local microbiota.

[0180] In the present disclosure, different probiotic strains are screened to identify strains that are stable when incubated in a warming solution simulating gastric acid of human gastric fluid. The strains tested in the present disclosure, including Lactobacillus acidophilus NCC 2628 (CNCM I-2453), Lactobacillus acidophilus NCC 2766 (CNCM I-3848), Lactobacillus acidophilus NCC 2775 (CNCM I-3851) and Lactobacillus acidophilus NCC 2619 (ATCC700396), are stable in a warming solution at a pH of about 1.5 for at least 10 minutes, at least 20 minutes, or at least 30 minutes; at a pH of about 2.6 for at least 10 minutes, at least 20 minutes, or at least 30 minutes; at a pH of about 3.4 for at least 60 minutes or at least 70 minutes.

[0181] In one embodiment, the isolated probiotic bacteria are able to survive in the acid environment of the human stomach for at least 10 minutes, at least 20 minutes, at least 30 minutes, at least 40 minutes, at least 50 minutes, at least 60 minutes, or at least 70 minutes.

[0182] In one embodiment, the composition is in the form of a capsule. In one embodiment, the isolated probiotics in the capsule can survive in the gastric acid environment of the human stomach for at least 10 minutes, at least 20 minutes, at least 30 minutes, at least 40 minutes, at least 50 minutes, at least 60 minutes, or at least 70 minutes.

[0183] In one embodiment, the capsule enables the isolated probiotic bacteria to survive in the acidic environment of the human stomach for at least 10 minutes, at least 20 minutes, at least 30 minutes, at least 40 minutes, at least 50 minutes, at least 60 minutes, at least 70 minutes, at least 80 minutes, at least 90 minutes, at least 100 minutes, at least 110 minutes, at least 2 hours, at least 3 hours, or at least 4 hours.

[0184] In one aspect, the present disclosure provides a method for increasing the production of agmatine and / or polyamines in a body part of a subject using a microbiota to provide certain health benefits to the subject, such as pain relief, anti-aging effects, neuroprotective and anti-depressant effects, improved vasodilation and metabolic health, improved cellular health and longevity. The method comprises administering a composition to the subject.

[0185] In one aspect, the present disclosure provides a method for improving pain relief, anti-aging effects, neuroprotective and anti-depressant effects, improved vasodilation and metabolic health, improved cellular health, and longevity in a subject in need thereof by increasing the production of agmatine and / or polyamines in a body part of a subject using a microbiota, the method comprising administering to the subject a composition discussed above and elsewhere in the present disclosure.

[0186] In one embodiment, the method further comprises administering to the subject an effective amount of the composition to provide at least 500 mg to 700 mg of arginine per day and / or at least 5 million CFU-7 million CFU of the isolated probiotic per day for at least 1 month, at least 3 months, or at least 6 months.

[0187] In one embodiment, the composition comprises a probiotic capable of colonizing and surviving in the gastrointestinal tract of a subject and further capable of increasing the production of agmatine in the gastrointestinal tract of the subject.

[0188] In one embodiment, the composition further comprises arginine.

[0189] In one embodiment, the composition further comprises a prebiotic. In one embodiment, the prebiotic is fructooligosaccharide (FOS) or galacto-oligosaccharide (GOS).

[0190] In one embodiment, the composition further comprises a cofactor, such as pyridoxal 5'-phosphate (PLP).

[0191] In one embodiment, the method further comprises separately administering to the subject an acidifying compound, such as a prebiotic, to adjust the pH of the GIT before or after administering the composition. In one embodiment, the acidifying compound is FOS.

[0192] In one embodiment, the body part of the subject is the gastrointestinal tract of the subject. In one embodiment, the production of agmatine and / or polyamines is at the gastrointestinal tract of the subject. In one embodiment, the production of agmatine is at the lower gastrointestinal tract of the subject. In one embodiment, the production of agmatine is at the lower gastrointestinal tract of the subject. In one embodiment, the production of agmatine is at the small intestine of the subject. In one embodiment, the production of agmatine is at the large intestine of the subject.

[0193] In one embodiment, the probiotic bacteria of separation is a bacterial strain that can convert arginine into agmatine and / or polyamines (such as putrescine, spermidine and spermine) in the gastrointestinal tract of the experimenter. In one embodiment, the probiotic bacteria of separation is a bacterial strain that can use arginine decarboxylase (ADC) to convert arginine into agmatine and / or polyamines (such as putrescine, spermidine and spermine). In one embodiment, the probiotic bacteria of separation is a bacterial strain that can use ornithine decarboxylase (ODC) to convert arginine into agmatine and / or polyamines (such as putrescine, spermidine and spermine). In one embodiment, the probiotic bacteria of separation is a bacterial strain that can promote the generation of arginine decarboxylase (ADC) in the gastrointestinal tract of the experimenter and use ADC to convert arginine into agmatine.

[0194] In one embodiment, the probiotic isolated is Lactobacillus acidophilus. In one embodiment, the composition comprises Lactobacillus acidophilus and arginine. In one embodiment, Lactobacillus acidophilus can convert arginine into agmatine and / or other polyamines (such as putrescine, spermidine and spermine) using arginine decarboxylase (ADC). In one embodiment, Lactobacillus acidophilus is a strain comprising an endogenous enzyme arginine decarboxylase (ADC).

[0195] In one embodiment, the isolated probiotic is a Lactobacillus acidophilus strain selected from Lactobacillus acidophilus NCC 2628 (CNCM 1-2453), Lactobacillus acidophilus NCC 2766 (CNCM 1-3848), Lactobacillus acidophilus NCC 2775 (CNCM 1-3851), Lactobacillus acidophilus NCC2619 (ATCC 700396) and combinations thereof.

[0196] In one embodiment, the isolated probiotic is a bacterial strain having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.5% or 99.9% sequence identity to one or more of Lactobacillus acidophilus NCC 2628 (CNCM I-2453), Lactobacillus acidophilus NCC 2766 (CNCM I-3848), Lactobacillus acidophilus NCC 2775 (CNCM I-3851), and Lactobacillus acidophilus NCC2619 (ATCC 700396).

[0197] In one embodiment, the isolated probiotic is a Lactobacillus acidophilus strain having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.5% sequence identity to one or more of Lactobacillus acidophilus NCC 2628 (CNCM I-2453), Lactobacillus acidophilus NCC 2766 (CNCM I-3848), Lactobacillus acidophilus NCC 2775 (CNCM I-3851), and Lactobacillus acidophilus NCC2619 (ATCC 700396).

[0198] In one embodiment, the composition is in the form of a dry powder, capsule, shelf-stable liquid, or a wet, frozen or shelf-stable paste. In one embodiment, the composition is a powder. In one embodiment, the composition is in the form of a capsule. In one embodiment, the composition is a dry powder and the isolated probiotic bacteria are coated on the composition or filled into the composition. In one embodiment, the isolated probiotic bacteria are active in the composition.

[0199] In one embodiment, the concentration of agmatine in the gastrointestinal tract of a subject about 24 hours after administration of the composition is at least 5 μM, at least 10 μM, at least 20 μM, at least 30 μM, at least 40 μM, at least 50 μM, at least 60 μM, at least 70 μM, at least 80 μM, at least 90 μM, at least 95 μM, at least 100 μM, at least 105 μM, at least 110 μM, at least 115 μM, at least 120 μM, at least 125 μM, or at least 130 μM.

[0200] In one embodiment, the subject can be a mammal, preferably a human, including adults and children.

[0201] In one aspect, the present disclosure provides an isolated probiotic capable of colonizing and surviving in the gastrointestinal tract of a subject, wherein the isolated probiotic is capable of producing agmatine from arginine in the gastrointestinal tract of the subject using a microbiota.

[0202] In one embodiment, the isolated probiotic is capable of using the microbiota to further use arginine decarboxylase (ADC) to produce agmatine from arginine in the gastrointestinal tract of the subject, and the isolated probiotic is a bacterial strain selected from Lactobacillus acidophilus NCC2628 (CNCM I-2453), Lactobacillus acidophilus NCC 2766 (CNCM I-3848), Lactobacillus acidophilus NCC 2775 (CNCM I-3851), Lactobacillus acidophilus NCC 2619 (ATCC 700396) and combinations thereof.

[0203] In one embodiment, the isolated probiotic is a bacterial strain having at least 90%, preferably at least 95% sequence identity with one or more of Lactobacillus acidophilus NCC 2628 (CNCM 1-2453), Lactobacillus acidophilus NCC 2766 (CNCM 1-3848), Lactobacillus acidophilus NCC 2775 (CNCM 1-3851) and Lactobacillus acidophilus NCC2619 (ATCC 700396).

[0204] In one embodiment, the isolated probiotic is a Lactobacillus acidophilus strain having at least 90%, preferably at least 95% sequence identity to one or more of Lactobacillus acidophilus NCC 2628 (CNCM 1-2453), Lactobacillus acidophilus NCC 2766 (CNCM 1-3848), Lactobacillus acidophilus NCC 2775 (CNCM 1-3851) and Lactobacillus acidophilus NCC2619 (ATCC 700396).

[0205] In one embodiment, the isolated probiotic is capable of producing agmatine from arginine using a microbiota in the gastrointestinal tract of a subject at a pH between about 4.0 and about 8.0.

[0206] In one embodiment, the isolated probiotic is capable of producing agmatine from arginine in the presence of fructooligosaccharides (FOS) using a microbiota in the gastrointestinal tract of a subject.

[0207] In one embodiment, the isolated probiotic is capable of producing agmatine from arginine in the gastrointestinal tract of a subject using microbiota and arginine decarboxylase (ADC) in the presence of the cofactor pyridoxal-5'-phosphate (PLP).

[0208] In one embodiment, the isolated probiotic has the ability to increase the bioavailability of agmatine produced from arginine in the gastrointestinal tract of a subject by delaying the conversion of agmatine to downstream polyamines for at least 24 hours.

[0209] In one embodiment, the isolated probiotic is capable of producing agmatine from arginine in the gastrointestinal tract of a subject using microbiota and arginine decarboxylase (ADC), wherein the concentration of agmatine is at least 20 μM 24 hours after administration of the isolated probiotic.

[0210] In one embodiment, the isolated probiotic bacteria is able to survive in a pH 2.6 environment for at least 10 minutes.

[0211] In one embodiment, the isolated probiotic bacteria is able to survive in a pH 3.4 environment for at least 60 minutes.

[0212] In one embodiment, the gastrointestinal tract of the subject is the lower gastrointestinal tract of the subject.

[0213] In one embodiment, the gastrointestinal tract of the subject is the large intestine of the subject.

[0214] In one aspect, the present disclosure provides a composition for increasing the production of agmatine in the gastrointestinal tract of a subject using a microbiota to provide health benefits to the subject, including pain relief, anti-aging effects, neuroprotective and anti-depressant effects, reduction in age-related memory loss, improved vasodilation and metabolic health, improved cellular health and longevity, the composition comprising: an isolated probiotic; and arginine, wherein the isolated probiotic is capable of colonizing and surviving in the gastrointestinal tract of the subject and is capable of producing agmatine from arginine in the gastrointestinal tract of the subject using the microbiota.

[0215] In one embodiment, the composition further comprises fructooligosaccharides (FOS) and / or GOS.

[0216] In one embodiment, the composition further comprises the cofactor pyridoxal 5'-phosphate (PLP).

[0217] In one embodiment, the composition further comprises one or more of a starch source, a protein source, a prebiotic source, a lipid source, vitamins, sugars, salts, spices, seasonings, minerals and flavoring agents.

[0218] In one embodiment, the composition is in the form of a capsule.

[0219] In one embodiment, the composition is in the form of a dry powder, and the isolated probiotic bacteria are filled into the composition.

[0220] In one embodiment, the isolated probiotic is active in the composition.

[0221] In one embodiment, the isolated probiotic is a Lactobacillus acidophilus strain having at least 90%, preferably at least 95% sequence identity to one or more of Lactobacillus acidophilus NCC 2628 (CNCM 1-2453), Lactobacillus acidophilus NCC 2766 (CNCM 1-3848), Lactobacillus acidophilus NCC 2775 (CNCM 1-3851) and Lactobacillus acidophilus NCC2619 (ATCC 700396).

[0222] In one embodiment, the isolated probiotic is a Lactobacillus acidophilus strain selected from Lactobacillus acidophilus NCC 2628 (CNCM 1-2453), Lactobacillus acidophilus NCC 2766 (CNCM 1-3848), Lactobacillus acidophilus NCC 2775 (CNCM 1-3851), Lactobacillus acidophilus NCC2619 (ATCC 700396) and combinations thereof.

[0223] In one aspect, the present disclosure provides a method for increasing the production of agmatine in the gastrointestinal tract of a subject using a microbiota to provide health benefits to the subject, including pain relief, anti-aging effects, neuroprotective and anti-depressant effects, reduced age-related memory loss, improved vasodilation and metabolic health, improved cellular health and longevity, the method comprising: administering to the subject a composition of claim 13, the composition comprising: an isolated probiotic; and arginine, wherein the isolated probiotic is capable of colonizing and surviving in the gastrointestinal tract of the subject and is capable of producing agmatine from arginine in the gastrointestinal tract of the subject using the microbiota.

[0224] In one embodiment, the composition is administered to a subject in an effective amount to provide the subject with a daily dose of the isolated probiotic in the range of 5M CFU-10 B CFU and a daily dose of arginine in the range of 500 mg-750 mg.

[0225] In one embodiment, the isolated probiotic is a Lactobacillus acidophilus strain having at least 90%, preferably at least 95% sequence identity to one or more of Lactobacillus acidophilus NCC 2628 (CNCM 1-2453), Lactobacillus acidophilus NCC 2766 (CNCM 1-3848), Lactobacillus acidophilus NCC 2775 (CNCM 1-3851) and Lactobacillus acidophilus NCC2619 (ATCC 700396).

[0226] In one embodiment, the isolated probiotic is a Lactobacillus acidophilus strain selected from Lactobacillus acidophilus NCC 2628 (CNCM 1-2453), Lactobacillus acidophilus NCC 2766 (CNCM 1-3848), Lactobacillus acidophilus NCC 2775 (CNCM 1-3851), Lactobacillus acidophilus NCC2619 (ATCC 700396) and combinations thereof.

[0227] In one embodiment, the subject is a human.

[0228] In one embodiment, the concentration of agmatine in the gastrointestinal tract of the subject is at least 20 μM at about 24 hours after administration of the composition.

[0229] In one aspect, the present disclosure provides a method for improving pain relief, anti-aging effects, neuroprotective and anti-depressant effects, improved vasodilation and metabolic health, improved cellular health, and longevity in a subject in need thereof by increasing the production of agmatine in the gastrointestinal tract of the subject using a microbiota, the method comprising administering to the subject the composition of claim 13.

[0230] Agmatine, produced by decarboxylation of arginine, is one of the precursors of polyamines such as putrescine, spermidine, and spermine in plant cells, prokaryotes, and some mammalian cells. Putrescine, spermidine, and spermine are essential for normal cell growth and survival. Spermidine is a cytoprotectant and inducer of autophagy, and its supplementation has been associated with anti-aging effects in preclinical and clinical trials [1,2]. Higher systemic and urinary polyamine levels are associated with growth in healthy children, but in the case of cancer, these molecules may also be associated with tumor progression [3,4].

[0231] In addition to being an intermediate in the production of polyamines, agmatine also induces a variety of physiological and pharmacological effects on the central nervous system and other organs [5,6]. Supplementation with synthetic agmatine has resulted in several health benefits. The most described and demonstrated benefits are the neuroprotective and antidepressant effects of agmatine, which are supported by several preclinical studies using animal models of cerebral ischemia, hypoxia, drug-based toxicity, or behavioral tests predicting antidepressant activity (tail suspension and forced swim tests) [7,8]. Clinical trials and several preclinical studies conducted on patients with radiculopathy have also well demonstrated the effects of agmatine supplementation on pain relief [6,7]. Early evidence (based on in vitro or ex vivo experiments) found effects of agmatine on vasodilation, improved metabolic health (stimulation of fatty acid oxidation, reduced lipid peroxidation, improved insulin signaling), and cellular health (reduction of oxidative stress, cytoprotective effects, proliferative effects, and antiproliferative effects) [5,6].

[0232] The mechanisms underlying the reported benefits of agmatine involve both non-receptor and receptor-based actions [5]. Agmatine activates α-2 adrenergic receptors and imidazoline receptors with high affinity (Ki 0.8 μM-164 μM for α-2 adrenergic receptors or 0.33 μM to >300 μM for imidazoline receptors) [5]. These triggers are involved in anti-inflammatory, nitric oxide regulation, Ca 2+ Second messengers for regulation, antioxidant activity, and cell survival in various tissues [9-11]. These receptors are distributed in several organs, including the brain (the most reported site of action), the gastrointestinal (GI) tract, and the liver [5]. Importantly, these receptors are not activated at physiological levels by spermidine, spermine, putrescine, or arginine

[12] .

[0233] Agmatine, putrescine, spermidine, and spermine also occur naturally in a variety of foods in free or conjugated form (e.g., phenolamides)

[13] . A significant proportion of systemic polyamines and agmatine may come from dietary sources, although the exact contribution is unknown

[14] . Assessing the contribution of dietary agmatine is even more difficult because daily consumption of agmatine has not been determined to the extent that we know of.

[0234] The free forms of dietary polyamines and agmatine are rapidly and efficiently absorbed in the upper GI tract, primarily in the stomach, duodenum, and jejunum

[15] . The limited recovery of agmatine and putrescine in the blood following dietary intervention with radiolabeled molecules suggests that the polyamines are rapidly absorbed and metabolized in the intestinal wall, liver, and / or other organs [16,17]. Dietary agmatine accumulates primarily in the liver and stomach wall

[15] . During fasting, significant luminal polyamine production and metabolic turnover is still found, probably due to microbial activity, pancreatic secretions, intestinal cell death, and mucosal production

[18] . In general, the order of magnitude of polyamines in the intestinal lumen is putrescine > spermidine > spermine

[17] . No information on luminal agmatine concentrations has been found.

[0235] Polyamines can also be produced by the gut microbiome, and in contrast to most mammalian cells where ornithine decarboxylase (ODC) is the rate-limiting enzyme, the major synthetic pathway is thought to be through arginine decarboxylase (ADC) and agmatine production

[17] . Given the efficient absorption of dietary polyamines in the upper GI tract, the presence of putrescine, spermidine, spermine, and agmatine in the ileum, cecum, and colon is primarily attributed to microbial activity

[17] . A novel hybrid mechanism for polyamine production has been described and requires the cooperation of several intestinal bacterial taxa cross-fed with agmatine

[19] . The presence of arginine, optimization of ADC activity, and acid production have been suggested to be key factors in promoting agmatine and polyamine production by this novel hybrid mechanism

[19] .

[0236] Luminal polyamines undergo enterohepatic circulation

[20] . However, polyamine absorption in the cecum and colon differs from that in the duodenum and jejunum, as a limited portion of these molecules is absorbed in the pancreaticobiliary fluid circulation

[17] . It is unclear how microbiome-derived polyamines are absorbed, redistributed, and metabolized in the host. There is no information on the exact contribution of microbial polyamines and agmatine to the overall molecular pool. Additional preclinical experiments with polyamines administered by enema are needed to clarify this. Luminal polyamines and agmatine may also be absorbed by enterocytes via active transporters, where they may confer local effects or be further exported to the host

[21] .

[0237] Limited data from rodents suggest that agmatine is most abundant in gastric, intestinal, and liver tissues

[20] . It is found in very low concentrations in the brain, although the brain is the most reported site of action

[22] . In rat tissues, agmatine appears to be 1 / 100 to 1 / 10 as abundant as spermine or spermidine, although this comparison needs to be made with caution as different rat species and analytical methods have been used in publications

[23] . In human urine and serum, agmatine, spermidine, and spermine are found in the same concentration range (approximately 0.5 μM)

[24] . The amount of agmatine in the human distal intestine is unknown, but limited data suggest that fecal agmatine levels are slightly higher (approximately 10 μmol / g dry matter) than putrescine or spermidine, suggesting that the gut microbiome can produce relatively high concentrations of agmatine and that this can override local effects, at least in the gut

[24] . Another study showed that putrescine is significantly higher than spermidine and can reach approximately 700 μM in healthy adults

[25] . Agmatine concentrations were not reported in this study

[25] . However, the lack of large and quantitative data in healthy adult populations makes it difficult to draw conclusions about the distribution of agmatine and polyamines in human biofluids. Polyamines and agmatine are rapidly reabsorbed and metabolized after meals or intravenous (IV) administration (the half-life of agmatine after IV injection is 5 minutes), suggesting that monitoring systemic polyamine levels may not be the best way to follow increases in intestinal polyamines [26,27]. Acetylated spermine and spermidine may be better candidates for following changes in polyamine pathways

[28] .

[0238] Promoting microbiome-derived polyamine pathways may have beneficial effects on the host, although the exact mechanisms and sites of interaction between intestinal polyamines remain unknown [29,30]. For example, a combination of arginine and Bifidobacterium LKM512 was found to increase intestinal microbial putrescine and spermidine in a mouse model compared with arginine alone, isolated probiotics, or controls, and the effect was abolished after antibiotic treatment. Six months of supplementation with this dual treatment improved lifespan and reduced age-related memory loss in the same mouse model compared with single treatments or controls

[31] . In a recent study in a mouse model of osteoporosis, Chevalier et al. demonstrated that the beneficial effects of temperature exposure on bone strength were mediated by changes in microbiome composition, functionality, and increases in bacterial polyamine synthesis pathways

[32] .

[0239] The present disclosure discloses compositions, such as compositions in capsule or powder form, to naturally increase agmatine and / or polyamines by promoting intestinal microbiome production. Applicants tested the following parameters using available in vitro intestinal models: 1) arginine source, agmatine precursors and polyamines; 2) intestinal acidification; and 3) addition of probiotics and / or cofactors to promote ADC and / or agmatine production.

[0240] Applicants have surprisingly discovered that increasing these metabolites such as agmatine and polyamines can induce local effects in the gut and potentially systemic effects.

[0241] Estimated concentrations of gut-derived agmatine and spermidine

[0242] Effective doses of polyamines and agmatine for specific benefits, as well as toxic doses, have been determined based on clinical and preclinical experiments using synthetic molecules

[33] . By calculating crude concentrations of human fecal and ileal polyamines, the applicants estimated that the intestinal luminal polyamine levels were below the synthetic doses required for beneficial or toxic doses. However, the estimated fecal agmatine and spermidine were above the doses required for mechanistic effects (based on receptor affinity or in vitro autophagy dose-response experiments). For example, agmatine can activate α-2 adrenergic receptors and imidazoline receptors, triggering mechanisms of action at low concentrations in the brain, stomach, or platelet membranes. Because G protein-coupled receptors (GPCRs) are also present in the intestine, local increases in agmatine in the ileum and colon may be sufficient to activate these receptors. Spermidine and agmatine concentrations in feces and in vitro batch fermentations and comparisons to concentrations required for biological effects (based on in vitro assays) are listed in Table 1 below.

[0243] Table 1: Spermidine and agmatine concentrations in feces, in vitro batch fermentation and comparison with concentrations required for biological effect Comparison (based on in vitro assay) .

[0244]

[0245] It is difficult to convert polyamine production from the in vitro intestinal model of the present disclosure into intestinal polyamine content where production, absorption and metabolism occur. The range of spermidine and agmatine concentrations from in vitro batch fermentation experiments is lower, but is in the same order of magnitude (μM) as those found in feces. The average agmatine and spermidine concentrations after arginine fermentation are already in the concentration range required for the mechanistic effect. However, the exact concentration that activates receptors or triggers autophagic effects in the intestine is unknown. In addition, the in vitro experimental results help establish target concentrations and utilize local effects on microbiome-derived polyamines. At the same time, it is difficult to estimate the target concentrations of agmatine and spermidine for the selection of ingredients disclosed in the present disclosure.

[0246] Ingredient Selection Criteria

[0247] Ingredients were selected to provide the highest and most significant increase in agmatine and spermidine production while limiting the production of putrescine, which has been associated with cancer progression in some cases. Synergistic effects between ingredient combinations were evaluated, and ingredients that improved product differentiation and communication were considered.

[0248] Further design of additional analyses

[0249] The inventors designed the MiniGut experiment to: 1) confirm agmatine-derived activation of GPCR receptors in healthy intestinal cells; 2) determine target concentrations for local dosing; and 3) provide the first evidence for the local effects of agmatine on intestinal health (i.e., cell proliferation, anti-inflammatory, and antioxidant).

[0250] Applicants have designed zebrafish and in vitro autophagy experiments to: 1) support early evidence that agmatine has anti-aging effects through autophagy activation; 2) compare the effects of agmatine with those of spermidine; and 3) identify target concentrations of agmatine required for an autophagy effect.

[0251] Applicants have designed an immunologically based assay.

[0252] Applicants also conducted studies on the CALM cohort to: 1) understand the association between microbial polyamines and agmatine and i) intestinal and ii) immune health in a free-living elderly population; and 2) understand how the amounts of microbial polyamines and agmatine are affected by specific protein-rich supplements (whey or collagen) in free-living elderly people.

[0253] Agmatine is an intermediate in the polyamine pathway. Agmatine is a biogenic amine produced by the decarboxylation of arginine. This reaction is carried out by arginine decarboxylase (ADC), which requires pyridoxal 5'-phosphate (PLP) as a cofactor. Agmatine is then partitioned into two major pathways. It is converted to putrescine by agmatinease, a precursor of the other polyamines spermidine and spermine; or it is converted to guanidinebutyraldehyde by amine oxidase or diamine oxidase (DAO)

[34] . The substrates and enzymes involved in agmatine homeostasis are shown in Figure 1

[34]

[0254] Agmatine and polyamines from different sources

[0255] diet :

[0256] Polyamines are found in a variety of foods. The total daily intake of polyamines (putrescine, spermidine, and spermine) in the European Union is 353.6 μmol / day of diet, with putrescine being the most abundant (211.9 μmol / day of diet), followed by spermidine (87 μmol / day of diet)

[35] . High agmatine concentrations are found in fermented foods such as alcoholic beverages (sake: 114 mg / L), sauerkraut brine (12 mg / L), and various seeds (lentils: 38 mg / kg, Alfafa fenugreek: 11 mg / kg, daikon: 52 mg / kg)

[14] . There are no reports of daily intake of agmatine

[14] . Seed germination results in an increase in agmatine and other polyamines

[36] . Figure 2The contents of agmatine (AGM), polyamines such as putrescine (PUT), cadaverine (CAD), spermidine (SPD), spermine (SPM) in seeds, sprouts and shoots of alfalfa are shown.

[36]

[0257] Phenolamides, defined as polyamines conjugated to phenolic compounds, are highly abundant in some plants and can be considered as a source of polyamines. Agmatine-conjugated phenolamides are found in wheat, rice, corn, and soybean; whereas hordatines (dimers of agmatine-conjugated phenolamides) are particularly nearly absent from hordeum. However, the bioavailability and digestibility of phenolamides require further investigation [13, 37].

[0258] Synthetic form :

[0259] Spermidine, agmatine, and arginine (precursors of these polyamines) are also available as supplement products (powders or capsules) to support a range of benefits. The benefits communicated are supported by various levels of evidence. Arginine or related polyamines in supplement products are listed in Table 2 below.

[0260] Table 2: Arginine or related polyamines in supplement products

[0261]

[0262] *: These supplements are often plant-based extracts that contain spermidine; and

[0263] **: No commercial products found

[0264] Endogenous production :

[0265] Polyamines in mammals are mainly produced through the arginine decarboxylase (ADC) and ornithine decarboxylase (ODC) pathways, such as Figure 3 However, ADC expression and agmatine production have been found in several mammalian cells including brain (glia, medulla), liver and kidney [38,39]. ADC is more frequently expressed in mitochondria than in the cytoplasm. The distribution of ADC in mammalian organs is different from that of agmatine, suggesting extracellular agmatine uptake [34,40]. Figure 3 The metabolism and transport of polyamines in mammalian cells and microbiota are shown.

[0266] Since agmatine is positively charged at physiological pH, it cannot cross the cellular lipid barrier by simple diffusion. Instead, agmatine uptake is mediated by an active polyamine transport system that includes a family of solute transporters (SLCs) with approximately 400 annotated members and an organic cation family (OCT) [8, 40]. Active agmatine efflux has been identified in human glioma cells

[22] , rat hepatocytes

[32] , rat arterial smooth muscle cells

[33] , and hamster kidney cells

[34] . Studies on six cell lines of human intestinal origin (Caco2, Cx1, Colo320, HT29, Colo205E, SW480) showed active agmatine uptake via agmatine-specific organic cation transporters [21, 41].

[0267] Gut Microbiome :

[0268] Prokaryotes can produce polyamines (such as Figure 3 However, ADC is thought to be the major pathway for the synthesis of polyamines by gut microbiota[40,42]. ADC has been characterized in several genera of enteric bacteria, highlighting the ability of the gut microbiome to produce agmatine

[34] .

[0269] Mastumoto et al. showed that the combination of arginine and Bifidobacterium species promoted the production of putrescine by bacteria

[29] . Figure 4 As shown, Kitada et al. further described a unique mechanism for polyamine production, which requires the cooperation of several taxa of intestinal bacteria

[19] . Several taxa of intestinal bacteria are described below. First, acid-tolerant bacteria such as Escherichia coli (E. coli) have an arginine-dependent acid-tolerant system (arginine-agmatine antiporter), which exports intracellular agmatine and imports extracellular arginine, and is strongly activated when the pH is below 6.5. The second type of intestinal bacteria is bacteria containing energy production systems, such as Enterococcus faecalis (agmatine deiminase). These bacteria lack ODC or ADC, but can import extracellular agmatine through the agmatine-putrescine antiporter to complete the production of polyamines and ATP. Third, acid-producing bacteria (e.g., Bifidobacterium animalis subsp. lactis) maintain environmental acidification. Among these various bacteria that follow independent survival strategies, agmatine is a key molecule in cross-feeding

[19] . Therefore, arginine supplementation, optimization of ADC activity, and acid production may be key factors in promoting agmatine and polyamine production. Figure 4 A hybrid mechanism of the putrescine production pathway consisting of cooperation between bacteria with an acid-resistant system and bacteria with an ATP synthesis system is shown.

[0270] Absorption and distribution of exogenous and microbiome-derived polyamines and agmatine in the intestine

[0271] Polyamines in the gastrointestinal lumen have different sources, such as from the diet, intestinal microbiota, pancreaticobiliary secretions, and intestinal dead cells. However, the precise contribution of each source to the total polyamine pool is unknown [18,40].

[0272] Dietary polyamines (putrescine, spermidine, and spermine) are rapidly absorbed in the lumen, primarily in the duodenum and jejunum

[18] . Studies focusing on luminal polyamine concentrations in normally fed male Sprague Dawley mice showed that putrescine concentrations were highest in the duodenum and upper jejunum (2000 nmol / g-3000 nmol / g wet tissue). The lowest concentrations were in the ileum. Spermine and spermine concentrations were, on average, 1 / 5 of putrescine concentrations. Maximum spermidine levels were found in the cecum (approximately 700 nmol / g wet tissue) and were absent in the ileum. Spermine concentrations were lowest and were only detectable in the duodenum and jejunum (100 nmol / g to 200 nmol / g wet tissue)

[17] . To further understand how polyamines are absorbed and redistributed in the billiarohepatic circulation, the bile duct was divided into the bile duct and the jejunum. 14 [C] Putrescine (1.6 nmol) was injected into different locations of the intestinal lumen, and the radioactivity was followed in the pancreaticobiliary secretions. The highest radioactivity recovery was found in the lower and upper jejunum within 60 min. Colonic injection induced an increase in radioactivity in the pancreaticobiliary secretions within the same time frame, although the recovery was much lower than that of jejunal injection. The ileal injection curve was different, as the radioactivity recovery was lower and longer, reaching a plateau at approximately 140 min after injection, indicating that the radioactivity was not absorbed in the ileum, but reached the cecum and colon before being absorbed

[17] .

[0273] In humans, for a 20-minute sampling period, fasting jejunal flow rates for putrescine, spermidine, and spermine were approximately 7000 nmol, 2000 nmol, and 500 nmol, respectively, highlighting important endogenous intestinal polyamine concentrations. After the test meal, putrescine flow rate increased by 25% in the jejunum, but no significant changes were found for the other polyamines, and no changes were observed in the ileum

[18] . Up to 20% of putrescine in the test meal was recovered in the blood, suggesting that most was metabolized in the intestinal wall and / or liver

[18] . In contrast, slight increases in acetylated putrescine and spermine / spermidine were found

[28] .

[0274] Rats ingested 14The distribution of radioactivity after [C]-agmatine administration showed that the stomach is the major site of absorption of exogenous agmatine [15, 20]. The highest levels of radioactivity were found in the liver, and significant amounts of radioactivity were also present in the stomach wall

[20] . Radioactivity was detected in the lumen of the ileum and colon after a 3-hour digestion period

[20] . Since it is unlikely that agmatine is transported to these intestinal segments without being absorbed, the authors proposed that the presence of radioactivity may be associated with the pancreaticobiliary fluid circulation [15, 20]. Radioactivity levels in the blood were low and varied greatly among subjects, highlighting the rapid redistribution of agmatine among organs

[20] .

[0275] Mucosal and luminal polyamine synthesis, attributed to mammalian and prokaryotic activities, was evaluated by monitoring the activities of ADC and ODC decarboxylases, respectively

[17] . In general, luminal ADC activity was higher than ODC activity, confirming that bacterial polyamine production occurs primarily through ADC activity. ADC and ODC activity were barely detectable in the duodenum and jejunum, whereas ADC activity was highest in the stomach, cecum, and colon, suggesting that bacterial polyamine production differs in the intestine. Interestingly, when luminal polyamine concentrations were high, mucosal ODC rates were low, except in the jejunum, which exhibited high putrescine levels and ODC activity

[17] .

[0276] Distribution of Agmatine and Polyamines in Mammalian Tissues .

[0277] Agmatine, spermine, and spermidine levels in rat tissues and human biofluids from different publications are summarized in Table 3. For the purpose of comparability between papers, concentrations were normalized to μM. Agmatine was most abundant in the stomach, small intestine, and large intestine tissues of Sprague-Dawley rats, with the highest level observed in the stomach being 0.071 μg / g wet tissue

[22] . The same order of magnitude was observed in male Long Evans rats of different ages

[22] . Concentrations of spermidine and spermine in Wistar rat tissues were 10 to 100 times higher than the highest levels found in the small intestine (213 μg / g and 100 μg / g wet tissue, respectively) and liver (230 μg / g and 235 μg / g wet tissue, respectively)

[23] . We cannot exclude that the variability in spermidine, spermine, and agmatine concentrations may be due, at least in part, to differences in rat species and analytical methods used in different publications [26, 43].

[0278] Table 3: Agmatine, spermine, and spermidine in rat tissues and human biofluids summarized from different publications Level [22-26,43,44]

[0279]

[0280] Rat blood concentrations of agmatine, spermine, and spermidine are significantly lower than those in other tissues, supporting earlier observations that these molecules are rapidly redistributed and / or metabolized in different tissues

[22] . Pharmacokinetic / pharmacodynamic (PK / PD) experiments showed that the half-life of agmatine in rat blood was approximately 5 minutes after a bolus injection (50 mg / kg)

[27] . Ten minutes after intravenous (IV) injection of radiolabeled polyamines in rats, plasma putrescine was reduced by 67%, spermine by 30%, and spermidine by 89%

[26] . Systemic polyamine levels may not be the best representation of the effective doses required for health benefits.

[0281] In human urine and serum, agmatine concentrations are in the same order of magnitude as spermidine and spermine. Swanson et al. found that agmatine concentrations in human fecal samples exceeded spermidine concentrations, ranging from 6 μmol / g dry matter to 13 μmol / g dry matter [24,25]. However, no additional publications directly comparing different polyamines in human biofluids and tissues are available to support these observations. Studies by Nestlé and published semiquantitative metabolomics data highlighted large interindividual variability in fecal agmatine levels in infants and adults with IBD. The lack of large and quantitative data in healthy adult populations makes it difficult to draw conclusions about the distribution of polyamines and agmatine in human biofluids.

[0282] Comparison of intestinal polyamines from batch fermentation and in vitro polyamine concentrations with oral polyamine doses, toxic doses and effective dose .

[0283] Applicants have attempted to compare the benefits and toxic doses of intestinal polyamine production with the average effective dose by calculating a rough estimate of the daily human feces and ileum content of polyamines and agmatine. Applicants have found that intestinal polyamine content is lower than the effective dose or toxic dose. However, the amount of agmatine and spermidine in feces is higher than the concentration required for the mechanism effect. Comparison of intestinal polyamines and in vitro polyamine concentrations from batch fermentation is shown in Table 4 with oral doses of polyamines, toxic doses, and effective doses.

[0284] Table 4: Comparison of intestinal polyamines from batch fermentation and in vitro polyamine concentrations and oral doses of polyamines, toxicity Dosage and effective dose .

[0285]

[0286]

[0287] *: Average value calculated based on the concentration at 6h+24h+48h-0h;

[0288] **Average concentration at 6h+24h-0h; and

[0289] ***No other references in the article

[0290] Health Benefits of Agmatine

[0291] The physiological relevance of endogenous agmatine remains unclear, but several health benefits have been attributed to synthetic agmatine supplementation. These benefits are graded based on the level of evidence [6] and include: 1) antidepressant effects and improved cognition (multiple preclinical evidence in several animal models); 2) pain relief and neuroprotection (several preclinical evidence and clinical trials); 3) vasodilation and cardioprotection (several in vitro studies and several preclinical evidence); 4) improved metabolic health (stimulation of fatty acid oxidation, glucose regulation) (few in vitro studies and preclinical evidence); 5) cellular health (reduction of oxidative stress, cytoprotection, proliferative effects, and antiproliferative effects) (few in vitro studies).

[0292] Further details on the evidence related to the potential clinical use of agmatine can be found in the review by Piletz et al. [6].

[0293] Mechanisms of action of agmatine in different tissues .

[0294] Mechanisms associated with the benefits of agmatine include anti-inflammatory, anti-apoptotic, antioxidant, inhibition of gliosis and edema, angiogenesis, neurogenicity, and clearance effects, depending on the target tissue.[6,7] These mechanisms are related to both receptor-based and non-receptor-based effects of agmatine.

[0295] Receptor-based effects

[0296] Agmatine binds with relatively high affinity to a range of receptors and binding sites as listed in Table 5 below.

[0297] Table 5: Affinity or potency of agmatine for various receptors and binding sites [5] .

[0298]

[0299]

[0300] Agmatine is an agonist for two types of GPCR receptors. Alpha-2 adrenergic receptors (also called α-2 adrenoceptors or α-2 adrenergic receptors) (affinity: Ki 0.8μM-164μM) and imidazoline receptors (affinity: Ki 0.33μM to >300μM) that trigger a series of signaling cascades. Four different subtypes of α-2 adrenoceptors have been characterized (α-2A, α-2B, α-2C, α-2D) and have been found in various organs including the brain, liver, gallbladder and gastrointestinal tract

[45] . These receptors have been identified in intestinal cell lines (HT29, Caco2-3B, enterochromaffin cells) and immune cells (rat kupffer cells coll and peritoneal monocyte macrophages) [45-50]. Alpha-2 adrenergic receptors are primarily identified in presynaptic and postsynaptic neurons, where they mediate inhibition of the central and peripheral nervous systems. Imidazoline (IL1) receptor activation is associated with neuroprotection, increased sodium and calcium excretion, changes in urine flow rate, and gastric motility [9,27,51,52]. It is also involved in blood pressure regulation and can act synergistically with alpha-2 adrenergic receptors

[51] . IL1 receptors are present in several organs, including the brain, liver, proximal digestive tract, GI tract (isolated piglet ileum, human colonic epithelial T 84 cell line), and lymphoid tissues (e.g., human peripheral blood mononuclear cells) [53,54].

[0301] These receptors regulate the phosphorylation of AKT and ERK1 / 2, CAMP and PKA, and JNK1 / 2, triggering the subsequent activation of transcription factors, including CREB and NRF2 [9,55]. CREB binds to the DNA sequence cAMP response element (CRE) and activates the transcription of genes that regulate different cellular responses. It promotes the transcription of brain-derived neurotrophic factor (BDNF), a key player in synaptic plasticity and memory processes

[56] . CREB was found to limit proinflammatory responses in T cells and B cells by inhibiting the NFkβ complex and activating IL-2, IL-6, IL-10, and TNF-α

[11] . During fasting, CREB activates gluconeogenesis and fat oxidation while inhibiting lipid storage and synthesis in the liver

[57] . NRF2 is another transcription factor that activates a series of cytoprotective genes involved in oxidative stress response (GSH production, ROS detoxification) and anti-inflammation [10,58].

[0302] Agmatine is a high affinity antagonist of the N-methyl-D-aspartate (NMDA) receptor (Table 5). NMDA plays an important role in synaptic plasticity and intracellular Ca2+ regulation

[59] . Its activation promotes neuronal survival and resistance to trauma in healthy conditions, but also triggers neuronal atrophy and cell death in pathological conditions (e.g., ischemia)

[60] . NMDA antagonists have been associated with a reduction in stress and antidepressant effects in treatment-resistant patients [59, 60].

[0303] Importantly, no studies have demonstrated activation of imidazoline or α-2-adrenergic receptors by spermidine, spermine, or putrescine. Arginine activates these receptors with much lower affinity (Ki 5 mM), suggesting that the effects of arginine on these receptors may be mediated by agmatine

[12] . However, spermidine and spermine can also inhibit NMDA receptors

[61] .

[0304] Non-receptor based effects

[0305] In several in vitro and in vitro cell assays, agmatine interferes with polyamine metabolism, nitric oxide synthase, and promotes antiproliferative effects at millimolar levels (1 mM for mouse renal proximal tubules, Ras-transformed NIH-3T3 fibroblasts, mouse glomerular mesangium, human Schwann tumor, rat glomerular endothelial cells, human colon cancer HT29 cells, and 0.01 mM for HTC rat hepatoma cells)

[41] . Intracellular concentrations of agmatine are accompanied by a decrease in the activity of the rate-limiting polyamine biosynthetic enzyme ODC, as well as a decrease in polyamine uptake and intracellular levels of putrescine and spermidine. This may be related to agmatine-induced activation of the protein anti-enzyme, which is involved in the autoregulation of polyamine content in cells

[62] . In contrast, agmatine is thought to activate polyamine catabolism through the activation of spermidine / spermine acetyltransferase (SSAT), resulting in an increase in acetylated polyamines

[28] . Acetylation of polyamines reduces their charge, altering their ability to bind to other macromolecules and changing their function. Acetylated polyamines can be further oxidized by acetylpolyamine oxidase or readily excreted from the cell

[63] . Injection of 456.6 mg / kg agmatine (ip) in suiss female mice demonstrated inhibition of ODC and activation of SSAT in the liver and kidney as well as a partial reduction in epithelial cell proliferation in the renal tubules

[64] . Based on these observations, agmatine is considered a potential tumor suppressor, however further preclinical studies are needed to confirm the antiproliferative effects of low and high doses of agmatine.

[0306] Enhancing the host benefits of microbiome-derived polyamines

[0307] Mastumoto and colleagues investigated the role of microbial polyamines in health benefits in several preclinical and clinical experiments [19, 25, 29-31]. They found that arginine intake (from 0 mg / g body weight to 9 mg / g body weight) increased fecal concentrations of putrescine and spermidine, which were eliminated after antibiotic use

[31] . Long-term intervention (6 months) with oral administration of arginine, the probiotic Bifidobacterium LKM512, or both was also tested. Compared with controls and single treatments, dual treatment reduced DNA damage (urinary 8-OHDG), improved aging markers (SMP-30) and lifespan, and reduced age-related memory loss

[31] .

[0308] In a randomized placebo-controlled trial, the same authors showed that 12 weeks of intervention with yogurt containing arginine (600 mg) and Bifidobacterium animalis subsp. Lactis improved endothelial function (increased reactive hyperemia index) in healthy individuals with a BMI of 25 (maximum in the healthy range)

[30] . In addition, fecal putrescine and serum spermidine concentrations were significantly higher in the treatment group than in the placebo group

[30] .

[0309] In a mouse model of osteoporosis, Chevalier et al. demonstrated that temperature exposure improved bone health by increasing cancellous bone volume, junction density, and thickness

[32] . Transplantation of the microbiota from temperature-treated mice into untreated mice reproduced these temperature-induced bone effects. Further metabolomic and metagenomic analyses revealed heat-associated changes in microbiome composition (expansion of Akkermansia muciniphila and Bacteroides and Alitsipes genera and decreases in bacteria from the genera Muribaculaceae or Lachnospirae) and an increase in bacterial polyamine synthesis capacity, resulting in higher cecal and fecal polyamine levels. Inhibition of polyamine synthesis by diamidinostatin limited the temperature-induced beneficial effects

[32] . Enhancing microbiome-derived polyamine biosynthetic pathways could have systemic effects on the host. However, the relationship between intestinal polyamines and the targeted benefits (memory loss, bone structure, endothelial function) remains unclear, as no evidence has been shown for intestinal polyamine transport to the site of action.

[0310] The present disclosure provides probiotics, compositions and methods for increasing the production of agmatine using a microbiota in order to provide certain health benefits to a subject.

[0311] Example

[0312] The following non-limiting examples support the concept of using microbiota to increase agmatine production.

[0313] Example 1

[0314] Materials and methods

[0315] Upper GIT digestion of selected products

[0316] A test product (protein 1) was made to pass completely through the oral, gastric and small intestinal stages, the latter involving absorption. This is considered important because the product contains a portion of digestible compounds that are converted into small molecules in the body and absorbed at the small intestinal level. In order to ensure the quality of its digestion protocol, ProDigest has updated its digestion method based on a common protocol developed within a large European framework (COST ActionInfoGest). The latter describes a static digestion method with the aim of enhancing the comparison of digestion experiments between research teams (Mackie and Rigby, 2015)3. ProDigest further improves the digestion method by combining a more accurate pH profile with a simulation of small intestinal absorption by means of a dialysis method. This simulation of small intestinal absorption by dialysis can remove small molecules from the intestinal digesta. For this purpose, a 14kDa dialysis membrane is used.

[0317] Storage of stool samples

[0318] Fecal material was collected from five healthy adult donors. A fecal suspension was prepared and mixed with an in-house optimized cryoprotectant. The obtained suspension was aliquoted, snap frozen, and then stored at -80°C (cryostock). Just before the experiment, the fecal samples were thawed and immediately added to the reactor.

[0319] Preparation of cold stocks from a single stool suspension ensures that the same microbial community is obtained in each aliquot, so the same inoculum is used throughout the different project phases. In addition, storage of aliquots ensures that the stored samples undergo only one freeze-thaw cycle before introduction into a given incubation, as new aliquots are used for each phase of the project. These measures ensure optimal reproducibility.

[0320] Short-term colon incubation

[0321] Short-term screening assays typically involve colonic incubation of a single dose of a test compound under conditions representative of the proximal large intestine using a bacterial inoculum from a selected donor as the source of microorganisms.

[0322] At the beginning of the short-term colonic incubation, the test components were added to a sugar-depleted nutrient medium containing colonic basal nutrients. Because the nutrients of this sugar-depleted nutrient medium will also be fermented by the colonic microbiota, a blank containing only sugar-depleted nutrient medium (without product) was included for each donor. Finally, a fecal inoculum of five donors was added (healthy adults with no history of antibiotic use 6 months before the experiment). Five treatments and one blank were tested per donor, resulting in the experimental settings provided in Table 6.

[0323] Table 6. Experimental samples .

[0324] Donor 1-5 condition Arginine FOS Protein 1 1 blank / / / 2 Arginine 3g / L / / 3 FOS / 3g / L / 4 Arginine + FOS 3g / L 3g / L / 5 Protein 1 / / ≤6g / L 6 Protein 1 + FOS / 3g / L ≤6g / L

[0325] The incubations were performed in single replicates, resulting in 30 independent incubations. The reactors were incubated for 48 hours at 37°C, shaking (90 rpm) and anaerobic conditions. The incubations were performed in fully independent reactors with sufficiently high volumes to not only ensure robust microbial fermentation, but also to allow collection of multiple samples over time. Sample collection enabled evaluation of metabolite production, thus understanding the complex microbial interactions that were occurring.

[0326] End point of the study

[0327] Changes in pH and gas, SCFA, ammonium and lactate production were assessed at the start of incubation and after 6, 24 and 48 hours. Quantitative deep shotgun sequencing was performed at the start of incubation and after 24 and 48 hours. Targeted metabolic analysis of 8 polyamines, amino acids and neurotransmitters was performed at the start of incubation and after 6, 24 and 48 hours.

[0328] Determination of protein and peptide / AA fractions in protein 1

[0329] The Kjeldahl procedure and TCA precipitation were applied to determine the protein and peptide / AA fractions in the original product Protein 1. Similarly, the small intestinal solution after upper GI passage and the supernatant after TCA precipitation were analyzed to determine the two product fractions. These calculations allowed the deduction of the actual product concentrations applied to the colonic incubations.

[0330] Total fermentation activity

[0331] pH: The degree of acidification during the experiment is a measure of the intensity of bacterial metabolism. The pH of the incubation provides a rough indication of the fermentation speed of the different tested products.

[0332] Gas Production: Colonic incubations are performed in a closed incubation system. This allows the evaluation of gas accumulation in the headspace, which can be measured with a manometer. Gas production is a measure of microbial activity and therefore of the fermentation rate of potential prebiotic substrates. H2 and CO2 are the first gases produced by microbial fermentation; they can subsequently be used as substrates for CH4 production, thereby reducing the gas volume. H2 can also be used to reduce sulfate to H2S, which is produced by proteolytic fermentation4. Therefore, N2, O2, CO2, H2 and CH4 account for 99% of intestinal gas. The remaining 1% is composed of NH3, H2S, volatile amino acids and short-chain fatty acids. 5

[0333] Changes in microbial metabolites

[0334] Short-chain fatty acid analysis: The pattern of SCFA production is an assessment of microbial carbohydrate metabolism (acetate, propionate, and butyrate) or protein metabolism (branched-chain SCFAs) and can be compared with the typical fermentation pattern of the normal GI microbiota.

[0335] Lactate Analysis: The human intestine carries lactate-producing and lactate-utilizing bacteria. Lactate is produced by lactic acid bacteria and lowers the pH of the environment, thereby also acting as an antimicrobial agent. Protonated lactic acid can penetrate microbial cells, after which it dissociates and releases intracellular protons, leading to acidification and microbial cell death. It can also be rapidly converted to propionate and butyrate by other microorganisms.

[0336] Ammonium analysis: Ammonium is a product of proteolytic degradation. Proteolytic fermentation leads to the production of potentially toxic or carcinogenic compounds such as p-cresol and p-phenol. Ammonium can be used as an indirect marker of low substrate availability.

[0337] Targeted metabolic analysis: Targets eight different polyamines, more specifically, putrescine, agmatine, acetylagmatine, ornithine, spermidine, spermine, citrulline, and 4-guanidinobutyric acid. In addition, samples are analyzed for the amino acid arginine and the neurotransmitter gamma-aminobutyric acid (GABA).

[0338] Microbial community composition and functional analysis

[0339] Initial QC, adapter trimming and preprocessing of metagenomic sequencing reads were performed using BBduk. Quality controlled reads were then translated and searched against the comprehensive and non-redundant protein sequence database UniRef 90 using Diamond. The UniRef90 database provided by UniProt represents a clustering of all non-redundant protein sequences in UniProt, so that each sequence in the cluster is arranged with 90% identity and 80% coverage of the longest sequence in the cluster. The mapping of metagenomic reads to gene sequences is weighted by mapping quality, coverage, and gene sequence length to estimate community-wide weighted gene family abundance, as described by Franzosa et al. 6. Gene families were then annotated as MetaCyc reactions (metabolic enzymes) to reconstruct and quantify MetaCyc metabolic pathways in the community, as described by Franzosa et al. In addition, UniRef_90 gene families were also regrouped into GO terms to obtain an overview of GO functions in the community. Finally, to facilitate comparison of multiple samples with different sequencing depths, abundance values ​​were normalized using total sum scaled (TSS) normalization to produce “copies per million” (similar to TPM in RNA-Seq) units.

[0340] Quantification of total bacterial cells by flow cytometry

[0341] Samples analyzed with shotgun sequencing were also analyzed with flow cytometry to determine the number of total bacterial cells, thus allowing the ratio values ​​obtained with shotgun sequencing to be converted to absolute quantities by multiplying the relative abundance of any population (at any phylogenetic level) in the sample by the total cell count obtained with the FC for a given sample. Samples were analyzed on a BD Facs verse. Samples were run using a high flow rate. Bacterial cells were separated from culture medium debris and signal noise by applying a threshold level of 200 on the SYTO channel. Appropriate parent and child gates were set to determine all populations.

[0342] Statistical analysis

[0343] In order to assess whether the difference between the treatment effects is statistically relevant at the endpoint studied, a paired two-sided T test was performed, taking into account all donors. When a large number of comparisons were made, in order to control the proportion of false discoveries, the Benjamini-Hochberg false discovery rate (FDR) was applied. When the p value obtained (obtained by paired two-sided T test) was less than the reference value (ref), the difference between the treatment effects was considered significant. The reference value was obtained by arranging the p values ​​obtained in ascending order within the donor group. The rank of a given p value is referred to as (i) and changes between 1 and the total amount of p values ​​(m=5; as described below). The reference value (ref=FDR*i / m) was calculated by multiplying the rank of the p value by FDR and then dividing it by the total amount of the comparisons performed. In order to compare the treatment effects in terms of pH, air pressure, microbial metabolite production (SCFA, lactic acid, ammonium and biogenic amines), functional curves and microbial community composition, FDR was set to 0.1, meaning that the lowest p value should be less than 0.02 to be significantly different, and the second lowest p value should be less than 0.04, etc. All calculations were performed by Microsoft Excel. The following five comparisons were conducted to evaluate:

[0344] The effects of arginine, protein 1 and FOS were calculated as the differences between these treatments and the corresponding blank (3 comparisons).

[0345] Effect of FOS in combination with arginine or protein 1: The differences between the combined treatments and the corresponding individual treatments (arginine and protein 1) were calculated (2 comparisons).

[0346] A systematic representation of these five comparisons is provided in Table 7.

[0347] Table 7: Systematic representation of five comparisons performed between treatments and corresponding reference conditions to evaluate the effects of treatment on metabolism Effects of markers and microbiome composition .

[0348]

[0349] The experimental results are shown in Figure 5 middle. Figure 5 The test results in clearly demonstrated that all five donors produced low concentrations of agmatine when only arginine was added to the fecal sample. In the absence of FOS (acidifying compound), donors A and E produced about 5 μM agmatine; donor B produced about 3 μM agmatine; while donors C and D did not produce agmatine.

[0350] Adding FOS in combination with arginine to the stool samples of five donors significantly increased the production of agmatine by about 10-fold. Samples from donors A, B, C, D, and E each produced about 12 μM, 5 μM, 17 μM, 8 μM, and 20 μM agmatine, respectively. Figure 5The test results showed that lower pH increased agmatine production by altering background metabolism. After 24 hours, a large amount of agmatine was completely consumed.

[0351] Example 2

[0352] Analyzing test results

[0353] Purpose

[0354] To support potential product input targeting agmatine production promotion, analytical work is required in this disclosure. The main objectives of the analytical work are: 1) to establish a new analytical platform within the group; 2) to develop analytical methods for the quantification of agmatine in bacterial culture media and semi-quantification of additional polyamines; and 3) to analyze and quantify the agreed compounds from the samples (n=611) received by HMI Group 4-providing analytical advice.

[0355] sample

[0356] Samples were generated at the Host-Microbe Interactions Group within the Institute of Health Sciences or externally. They were generated in various batches of experiments and collected in Eppendorf tubes. Samples were shipped in batches to the EPFL site for analysis and stored at -80 °C until the day of analysis after each experimental run.

[0357] Analytical methods

[0358] The protein and peptide panels within NIFSAS are extensively provided by liquid chromatography coupled to a high resolution mass spectrometer (LC-HRMS). Analytical work has been performed to: 1) quantify agmatine, and 2) only semi-quantify additional polyamine compounds and compounds associated with metabolic pathways (i.e., acetylagmatine, gamma-aminobutyric acid, citrulline, arginine, ornithine, putrescine, spermidine, and spermine) using external calibration methods.

[0359] Analytical methods

[0360] Sample preparation

[0361] All samples were prepared according to an in-house developed analytical method reported in R&D Memo: “Polyamines in bacterial media–Analytical approach using LC-HRMS”. The calibration range was defined as developed and then adjusted based on the calculated concentration of each analyte found in unknown samples and the analytical limit to minimize >ULOQ results.

[0362] Experimental Results

[0363] Analysis and evaluation

[0364] Each analytical series was evaluated for each compound of interest. In each analytical series, a calibration curve with 6 QC samples at 3 different levels was injected with the unknown samples. When the number of unknown samples was >80, a second calibration curve with another 3 QC samples was then injected at the end of the analytical sequence. The R of the calibration curves was checked according to the R&D Memo as previously described. 2 , CV of individual standard points and CV of QC.

[0365] Individual strain selection and time course experiments (77 samples received and analyzed)

[0366] The aim of this experiment was to identify the most relevant time points for potential agmatine production. To this end, 6 different single strains were cultured under anaerobic conditions to evaluate their influence on agmatine production. Samples were measured at 5 hours (T5h), 24 hours (T24h) and 48 hours (T48h). The test results of the evolution of agmatine concentration over time (T5h, T24h, T48h) of the strain screening are shown in Figure 6 In. By Figure 6 It can be seen that the agmatine concentration reached a maximum at T24h before decreasing. Further analysis focused on T24h for potential significant agmatine production.

[0367] Example 3

[0368] "Test tube and batch" fermentation (48 samples received and analyzed)

[0369] The purpose of this experiment was to select the best conditions for internal fermentation to obtain the highest agmatine concentration. For this purpose, 8 donors (fecal extracts) were selected and incubated to evaluate the best fermentation conditions. Seven donor extracts were analyzed at 0 hours (T0h), 6 hours (T6h) and 24 hours (T24h). The test results of the effect of test tube and batch fermentation on agmatine concentration are shown in Figure 7 middle. Figure 7 The test results in clearly demonstrated that tube fermentation showed the highest agmatine production (up to 10 times that of batch fermentation). This was the fermentation of choice for further experiments.

[0370] Example 4

[0371] Tube / strain combinations (447 samples received; 200 samples analyzed)

[0372] The aim of this experiment was to investigate whether the combination of a specific strain with arginine could lead to an increase in agmatine production.

[0373] For this purpose, 3 donors from previous experiments (low, medium and high agmatine producers) were selected and incubated with 7 different single strains and 1 strain combination. Priority samples were identified within the group and samples of specific donors (donors 1, 4 and 8) were analyzed at 0 hours (T0h), 6 hours (T6h) and 24 hours (T24h). The results of the tests on the effect of strains with various donors on agmatine production are shown in Fig. 8A and Figure 8B In the figure, (A) represents the total ratio, and (B) represents the amplified ratio from 0 μM to 50 μM. Fig. 8A and Figure 8B As shown, agmatine concentrations increased in the three donors when incubated with the specific strains.

[0374] Fig. 8A and Figure 8B The test results in clearly demonstrate the following observations: 1) a positive effect on agmatine concentration was observed when Dolphilus 606, NCC3001 was incubated with donor 1; 2) a positive effect on agmatine concentration was observed when Lacto679, NCC3001 was incubated with donor 4; and 3) a positive effect on agmatine concentration was observed when Dolphilus 606, Thermo511 was incubated with donor 8. This variability may indicate a donor-dependent response to agmatine after arginine supplementation.

[0375] The remaining samples were stored at -80°C for analysis, should the group require them. These results allowed the design of 4 different mixtures to be incubated with specific donors for the selection of the blended mixtures to be produced.

[0376] Example 5

[0377] Effect of pH

[0378] In the test tube / strain combination experiments, two pH conditions of 5.0 and 7.0 were evaluated (pH 5 and pH 7). Fig. 9 Results showing the effect of different pH conditions on the agmatine concentration obtained for Donor 1. Fig. 9 The test results in clearly demonstrated that pH 7 conditions always resulted in higher agmatine production (up to 3 times that of pH 5 conditions), except when strain Thermo511 of the strain combination was applied. Controlling pH as much as possible is key in agmatine production. In the presence of bacteria, neutral pH conditions of 7.0 resulted in higher agmatine production in the samples.

[0379] Example 6

[0380] Strain research (24+36 samples)

[0381] The purpose of these experiments was to evaluate different NCC strains and obtain potential candidates as promoters of agmatine production. For this purpose, donor 1 (a medium agmatine producer) from the previous experiment was selected and incubated with 22 different NCC strains in the first batch. The T24h samples were analyzed. The results of the tests on the effect of various strains incubated with donor 1 on the concentration of agmatine are shown in Fig.10 , the figure clearly demonstrates that 4 specific strains (NCC2619, NCC2628, NCC2766 and NCC2775) sharply increased agmatine concentration at T24h, as shown in Fig.10 shown.

[0382] To confirm the beneficial effect on agmatine production, a second experiment investigated the incubation of reduced numbers of strains with Donor 1. T0, T6h, T24h and T48h samples were analyzed and the experimental data on the effect of specific strains incubated with Donor 1 on agmatine concentrations are shown in Fig.11 middle.

[0383] Fig.11 The test results in clearly confirmed the previous findings that 4 specific strains (NCC2619, NCC2628, NCC2766 and NCC2775) significantly promoted agmatine production at the maximum agmatine concentration at 24 hours (under these specific sampling conditions).

[0384] Example 7

[0385] The purpose of this experiment was to evaluate the effect of 4 different strains of Lactobacillus acidophilus on the production and bioavailability of agmatine using in vitro arginine fermentation. In vitro fermentation of arginine was performed using stool samples from 5 donor candidates prepared and tested in Example 1. The microbiota was supplemented with 4 different strains of Lactobacillus acidophilus (NCC2619, NCC2628, NCC2766 and NCC2775).

[0386] Agmatine concentrations were assessed over a 48 hour time course to evaluate agmatine bioavailability.

[0387] All four strains of Lactobacillus acidophilus (NCC2619, NCC2628, NCC2766 and NCC2775) increased the total concentration of agmatine and thus its bioavailability. Such increased concentrations were associated with a decrease in pH.

[0388] in conclusion

[0389] The polyamine method using LC-HRMS developed and reported above was suitable for the purpose of measuring the 385 samples received from stream 1 within the framework of the project Magma. The absolute quantification of agmatine allowed the applicant to select the best fermentation conditions and strains to increase the agmatine concentration. All polyamines and related compounds (such as acetylagmatine, γ-aminobutyric acid, citrulline, arginine, agmatine, ornithine, putrescine, spermidine and spermine) were also measured in each sample.

[0390] Various changes and modifications made to the currently preferred embodiments disclosed herein will be apparent to those skilled in the art. These changes and modifications may be made without departing from the spirit and scope of the subject matter of the present invention and without diminishing its expected advantages. Therefore, such changes and modifications are intended to be covered by the appended claims.

[0391] References

[0392] 1. Madeo, F., et al., Spermidine: a physiological autophagy inducer acting as an anti-aging vitamin in humans, Autophagy, 2019.15(1):p.165-168.

[0393] 2.Igarashi,K.and K.Kashiwagi,The functional role of polyamines ineukaryotic cells.Int J Biochem Cell Biol, 2019.107:p.104-115.

[0394] 3. Thomas, T. and TJ Thomas, Polyamine metabolism and cancer. J Cell MolMed, 2003.7(2):p.113-26.

[0395] 4. Madeo, F., et al., Spermidine in health and disease. Science, 2018.359(6374).

[0396] 5.Molderings,G.J.and B.Haenisch,Agmatine(decarboxylated L-arginine):physiological role and therapeutic potential.Pharmacol Ther,2012.133(3):p.351-65.

[0397] 6.Piletz,J.E.,et al.,Agmatine:clinical applications after 100years intranslation.Drug Discov Today,2013.18(17-18):p.880-93.

[0398] 7.Freitas,A.E.,V.B.Neis,and A.L.S.Rodrigues,Agmatine,a potentialnovel therapeutic strategy for depression.Eur Neuropsychopharmacol,2016.26(12):p.1885-1899.

[0399] 8.Laube,G.and H.G.Bernstein,Agmatine:multifunctional argininemetabolite and magic bullet in clinical neuroscience,Biochem J,2017.474(15):p.2619-2640.

[0400] 9.Raasch,W.,et al.,Biological significance of agmatine,an endogenousligand at imidazoline binding sites.Br J Pharmacol,2001.133(6):p.755-80.

[0401] 10.Tonelli,C.,I.I.C.Chio,and D.A.Tuveson,Transcriptional Regulationby Nrf2.Antioxid Redox Signal,2018.29(17):p.1727-1745.

[0402] 11.Wen,A.Y.,K.M.Sakamoto,and L.S.Miller,The role of the transcriptionfactor CREB in immune function.J Immunol,2010.185(11):p.6413-9.

[0403] 12.Joshi,M.S.,et al.,Receptor-mediated activation of nitric oxidesynthesis by arginine in endothelial cells.Proc Natl Acad Sci U S A,2007.104(24)p.9982-7.

[0404] 13.Bassard,J.E.,et al.,Phenolamides:bridging polyamines to thephenolic metabolism.Phytochemistry,2010.71(16):p.1808-24.

[0405] 14.Galgano,F.,et al.,Focused review:agmatine in fermented foods.FrontMicrobiol,2012.3:p.199.

[0406] 15.Molderings,G.J.,et al.,Gastrointestinal uptake of agmatine:distribution in tissues and organs and pathophysiologic relevance.Ann N YAcad Sci,2003.1009:p.44-51.

[0407] 16.Milovic,V.,Polyamines in the gut lumen:bioavailability andbiodistribution.Eur J Gastroenterol Hepatol,2001.13(9):p.1021-5.

[0408] 17.Osborne,D.L.and E.R.Seidel,Gastrointestinal luminal polyamines:cellular accumulation and enterohepatic circulation.Am J Physiol,1990.258(4Pt 1):p.G576-84.

[0409] 18.Benamouzig,R.,et al.,Fasting and postprandial polyamineconcentrations in the human digestive lumen.Am J Clin Nutr,1997.65(3):p.766-70.

[0410] 19.Kitada,Y.,et al.,Bioactive polyamine production by a novel hybridsystem comprising multiple indigenous gut bacterial strategies.Sci Adv,2018.4(6):p.eaat0062.

[0411] 20.Molderings,G.J.,et al.,Exposure of rat isolated stomach and ratsin vivo to[(14)C]agmatine:accumulation in the stomach wall and distributionin various tissues.Fundam Clin Pharmacol,2002.16(3):p.219-25.

[0412] 21.Heinen,A.,et al.,Pharmacological characteristics of the specifictransporter for the endogenous cell growth inhibitor agmatine in six tumorcell lines.Int J Colorectal Dis,2003.18(4):p.314-9.

[0413] 22.Raasch,W.,et al.,Agmatine,the bacterial amine,is widelydistributed in mammalian tissues.Life Sci,1995.56(26):p.2319-30.

[0414] 23.Jaenne,J.,A.Raina,and M.Siimes,Spermidine and Spermine in RatTissues at Different Ages.Acta Physiol Scand,1964.62:p.352-8.

[0415] 24.Swanson,K.S.,et al.,Fructooligosaccharides and Lactobacillusacidophilus modify bowel function and protein catabolites excreted by healthyhumans.J Nutr,2002.132(10):p.3042-50.

[0416] 25.Matsumoto,M.,K.Kakizoe,and Y.Benno,Comparison of fecal microbiotaand polyamine concentration in adult patients with intractable atopicdermatitis and healthy adults.Microbiol Immunol,2007.51(1):p.37-46.

[0417] 26.Rosenthal,S.M.and C.W.Tabor,The pharmacology of spermine andspermidine;distribution and excretion.J Pharmacol Exp Ther,1956.116(2):p.131-8.

[0418] 27.Raasch,W.,et al.,Agmatine,an endogenous ligand at imidazolinebinding sites,does not antagonize the clonidine-mediated blood pressurereaction.Br J Pharmacol,2002.135(3):p.663-72.

[0419] 28.Rosenblum,M.G.and D.H.Russell,Conjugation of radiolabeledpolyamines in the rat.Cancer Res,1977.37(1):p.47-51.

[0420] 29.Matsumoto,M.,et al.,Longevity in mice is promoted by probiotic-induced suppression of colonic senescence dependent on upregulation of gutbacterial polyamine production.PLoS One,2011.6(8):p.e23652.

[0421] 30.Matsumoto,M.,Y.Kitada,and Y.Naito,Endothelial Function is improvedby Inducing Microbial Polyamine Production in the Gut:A Randomized Placebo-Controlled Trial.Nutrients,2019.11(5).

[0422] 31.Kibe,R.,et al.,Upregulation of colonic luminal polyamines producedby intestinal microbiota delays senescence in mice.Sci Rep,2014.4:p.4548.

[0423] 32.Chevalier,C.,et al.,Warmth Prevents Bone Loss Through the GutMicrobiota.Cell Metab,2020.32(4):p.575-590 e7.

[0424] 33.Til,H.P.,et al.,Acute and subacute toxicity of tyramine,spermidine,spermine,putrescine and cadaverine in rats.Food Chem Toxicol,1997.35(3-4):p.337-48.

[0425] 34.Haenisch,B.,et al.,Regulatory mechanisms underlying agmatinehomeostasis in humans.Am J Physiol Gastrointest Liver Physiol,2008.295(5):p.G1104-10.

[0426] 35.Bardócz,S.,et al.,Polyamines in food—implications for growth andhealth.Journal of Nutritional Biochemistry,1993.

[0427] 36.Kralj Cigic,I.,et al.,Accumulation of Agmatine,Spermidine,andSpermine in Sprouts and Microgreens of Alfalfa,Fenugreek,Lentil,and DaikonRadish.Foods,2020.9(5).

[0428] 37.Wang,W.,H.D.Snooks,and S.Sang,The Chemistry and Health Benefits ofDietary Phenolamides.J Agric Food Chem,2020.68(23):p.6248-6267.

[0429] 38.Lortie,M.J.,et al.,Agmatine,a bioactive metabolite ofarginine.Production,degradation,and functional effects in the kidney of therat.J Clin Invest,1996.97(2):p.413-20.

[0430] 39.Zhu,M.Y.,et al.,Expression of human arginine decarboxylase,thebiosynthetic enzyme for agmatine.Biochim Biophys Acta,2004.1670(2):p.156-64.

[0431] 40.Ramos-Molina,B.,et al.,Dietary and Gut Microbiota Polyamines inObesity-and Age-Related Diseases.Front Nutr,2019.6:p.24.

[0432] 41.Mayeur,C.,et al.,Effects of agmatine accumulation in human coloncarcinoma cells on polyamine metabolism,DNA synthesis and the cellcycle.Biochim Biophys Acta,2005.1745(1):p.111-23.

[0433] 42.Burrell,M.,et al.,Evolution and multiplicity of argininedecarboxylases in polyamine biosynthesis and essential role in Bacillussubtilis biofilm formation.J Biol Chem,2010.285(50):p.39224-38.

[0434] 43.Zhao,S.,et al.,Determination of agmatine in biological samples bycapillary electrophoresis with optical fiber light-emitting-diode-inducedfluorescence detection.J Chromatogr A,2006.1123(1):p.138-41.

[0435] 44.Forget,P.,et al.,Fecal polyamine concentration in children withand without nutrient malabsorption.J Pediatr Gastroenterol Nutr,1997.24(3)p.285-8.

[0436] 45.Bouscarel,B.,et al.,alpha 2-Adrenoceptors in the HT 29 human colonadenocarcinoma cell line:characterization with[3H]clonidine;effects on cyclicAMP accumulation.Eur J Pharmacol,1985.107(2):p.223-31.

[0437] 46.Schaak,S.,et al.,Alpha(2)adrenoceptors regulate proliferation ofhuman intestinal epithelial cells.Gut,2000.47(2):p.242-50.

[0438] 47.Zhou,M.,et al.,The role of Kupffer cell alpha(2)-adrenoceptors innorepinephrine-induced TNFalpha production.Biochim Biophys Acta,2001.1537(1):p.49-57.

[0439] 48.Sud,R.,et al.,Antinociception occurs with a reversal in alpha 2-adrenoceptor regulation of TNF production by peripheral monocytes / macrophagesfrom pro-to anti-inflammatory.Eur J Pharmacol,2008.588(2-3):p.217-31.

[0440] 49.Bellono,N.W.,et al.,Enterochromaffin Cells Are Gut Chemosensorsthat Couple to Sensory Neural Pathways.Cell,2017.170(1):p.185-198 e16.

[0441] 50.Szelenyi,J.,et al.,Contribution of differently localized alpha 2-and beta-adrenoceptors in the modulation of TNF-alpha and IL-10 production inendotoxemic mice.Ann N Y Acad Sci,2000.917:p.145-53.

[0442] 51.Maltsev,A.V.,et al.,Alpha-2 adrenoceptors and imidazolinereceptors in cardiomyocytes mediate counterbalancing effect of agmatine on NOsynthesis and intracellular calcium handling.J Mol Cell Cardiol,2014.68:p.66-74.

[0443] 52.Zadori,Z.S.,et al.,Evidence for the gastric cytoprotective effectof centrally injected agmatine.Brain Res Bull,2014.108:p.51-9.

[0444] 53.Molderings,G.J.,et al.,Imidazoline recognition sites and stomachfunction.Ann N Y Acad Sci,1999.881:p.332-43.

[0445] 54.Li,X.,et al.,Agmatine Protects Against the Progression of SepsisThrough the Imidazoline I2 Receptor-Ribosomal S6 Kinase 2-Nuclear Factor-kappaB Signaling Pathway.Crit Care Med,2020.48(1):p.e40-e47.

[0446] 55.Zhang,J.,M.M.El-Mas,and A.A.Abdel-Rahman,Imidazoline I(1)receptor-induced activation of phosphatidylcholine-specific phospholipase C elicitsmitogen-activated protein kinase phosphorylation in PC12 cells.Eur JPharmacol,2001.415(2-3):p.117-25.

[0447] 56.Miranda,M.,et al.,Brain-Derived Neurotrophic Factor:A Key Moleculefor Memory in the Healthy and the Pathological Brain.Front Cell Neurosci,2019.13:p.363.

[0448] 57.Herzig,S.,et al.,CREB controls hepatic lipid metabolism throughnuclear hormone receptor PPAR-gamma.Nature,2003.426(6963):p.190-3.

[0449] 58.Loboda,A.,et al.,Role of Nrf2 / HO-1 system in development,oxidativestress response and diseases:an evolutionarily conserved mechanism.Cell MolLife Sci,2016.73(17):p.3221-47.

[0450] 59.Zhu,S.,et al.,Mechanism of NMDA Receptor Inhibition andActivation.Cell,2016.165(3):p.704-14.

[0451] 60.Papadia,S.and G.E.Hardingham,The dichotomy of NMDA receptorsignaling.Neuroscientist,2007.13(6):p.572-9.

[0452] 61.Rock,D.M.and R.L.MacDonald,Spermine and related polyamines producea voltage-dependent reduction of N-methyl-D-aspartate receptor single-channelconductance.Mol Pharmacol,1992.42(1):p.157-64.

[0453] 62.Satriano,J.,et al.,Agmatine suppresses proliferation by frameshiftinduction of antizyme and attenuation of cellular polyamine levels.J BiolChem,1998.273(25):p.15313-6.

[0454] 63.Pegg,A.E.,Spermidine / spermine-N(1)-acetyltransferase:a keymetabolic regulator.Am J Physiol Endocrinol Metab,2008.294(6):p.E995-1010.

[0455] 64.Dudkowska,M.,et al.,Agmatine modulates the in vivo biosynthesisand interconversion of polyamines and cell proliferation.Biochim BiophysActa,2003.1619(2):p.159-66.

[0456]

[0457]

[0458]

Claims

1. A method for improving pain relief, anti-aging effects, neuroprotective and anti-depressant effects, improved vasodilation and metabolic health, improved cellular health, and lifespan, and / or reducing age-related memory loss in a subject in need thereof, the method comprising administering to the subject an effective amount of a composition comprising an isolated probiotic and arginine to increase the production of agmatine in the gastrointestinal tract of the subject.

2. The method of claim 1, wherein the isolated probiotic comprises a strain of Lactobacillus acidophilus.

3. The method according to claim 1, wherein the isolated probiotic comprises a bacterial strain having at least 90%, preferably at least 95%, sequence identity with a strain selected from the group consisting of Lactobacillus acidophilus NCC2628 (CNCM I-2453), Lactobacillus acidophilus NCC 2766 (CNCM I-3848), Lactobacillus acidophilus NCC 2775 (CNCM I-3851) and Lactobacillus acidophilus NCC 2619 (ATCC 700396).

4. The method of claim 1, wherein the composition further comprises an ingredient selected from the group consisting of a starch source, a protein source, a prebiotic source, a lipid source, vitamins, sugars, salts, spices, seasonings, minerals, flavoring agents, and combinations thereof.

5. The method of claim 1, wherein the isolated probiotic comprises a Lactobacillus acidophilus strain selected from the group consisting of Lactobacillus acidophilus NCC 2628 (CNCMI-2453), Lactobacillus acidophilus NCC 2766 (CNCM I-3848), Lactobacillus acidophilus NCC 2775 (CNCM I-3851), Lactobacillus acidophilus NCC 2619 (ATCC 700396), and combinations thereof.

6. The method of claim 1, wherein the isolated probiotic catalyzes the production of agmatine from arginine in the gastrointestinal tract of the subject using arginine decarboxylase (ADC) and local microflora, wherein the concentration of agmatine in the gastrointestinal tract of the subject is at least 20 μM 24 hours after administration of the composition.

7. The method of claim 6, wherein the concentration of agmatine in the gastrointestinal tract of the subject is at least 100 μM about 24 hours after administration of the composition.

8. The method of claim 1, wherein the isolated probiotic increases the bioavailability of agmatine produced from arginine in the gastrointestinal tract of the subject by delaying the conversion of agmatine to downstream polyamines for at least 24 hours.

9. The method according to claim 1, wherein the composition is in the form of dry powder and the isolated probiotic bacteria are filled into the composition.

10. The method of claim 1, wherein the isolated probiotic is active in the composition.

11. The method of claim 9, wherein the composition is in the form of a capsule.

12. The method of claim 11, wherein the isolated probiotic bacteria in the capsule are capable of surviving in a pH 1.5 fluid environment for at least 30 minutes.

13. The method of claim 11, wherein the isolated probiotic bacteria in the capsule are capable of surviving in a pH 3.5 fluid environment for at least 90 minutes.

14. The method of claim 10, wherein the isolated probiotic bacteria is able to survive in a pH 1.5 fluid environment for at least 10 minutes.

15. The method of claim 10, wherein the isolated probiotic bacteria is capable of surviving in a pH 3.5 fluid environment for at least 60 minutes.

16. The method of claim 1, wherein the gastrointestinal tract of the subject is the lower gastrointestinal tract of the subject.

17. The isolated probiotic of claim 1, wherein the gastrointestinal tract of the subject is the large intestine of the subject.

18. The method of claim 1, wherein the composition is administered to the subject in an effective amount to provide the subject with a daily dose of the isolated probiotic in an amount of at least 5 million CFU and a daily dose of the arginine in an amount of 500 mg to 700 mg.

19. The method of claim 1, wherein the subject is a human.

20. The method of claim 1, further comprising administering a prebiotic to the subject before or after administering the composition.

21. A composition comprising an isolated probiotic and arginine, wherein the isolated probiotic comprises a bacterial strain having at least 90%, preferably at least 95%, sequence identity with a strain selected from the group consisting of Lactobacillus acidophilus NCC 2628 (CNCM I-2453), Lactobacillus acidophilus NCC 2766 (CNCM I-3848), Lactobacillus acidophilus NCC 2775 (CNCMI-3851) and Lactobacillus acidophilus NCC 2619 (ATCC 700396).

22. The composition of claim 21, wherein the composition further comprises an ingredient selected from the group consisting of a starch source, a protein source, a prebiotic source, a lipid source, vitamins, sugars, salts, spices, seasonings, minerals and flavoring agents.

23. The composition of claim 21, wherein the isolated probiotic comprises a live bacterial strain.

24. The composition of claim 23, wherein the isolated probiotic bacteria is able to survive in a pH 1.5 fluid environment for at least 10 minutes.

25. The composition of claim 23, wherein the isolated probiotic bacteria is capable of surviving in a pH 3.5 fluid environment for at least 60 minutes.

26. The composition of claim 21, wherein the composition is in the form of a capsule.

27. The composition of claim 26, wherein the isolated probiotic bacteria in the capsule are capable of surviving in a pH 1.5 fluid environment for at least 30 minutes.

28. The composition of claim 26, wherein the isolated probiotic bacteria in the capsule are capable of surviving in a pH 3.5 fluid environment for at least 90 minutes.

29. The composition of claim 21, wherein the composition is in the form of a dry powder.

30. The composition of claim 21, wherein the isolated probiotic comprises a Lactobacillus acidophilus strain selected from the group consisting of Lactobacillus acidophilus NCC 2628 (CNCM I-2453), Lactobacillus acidophilus NCC 2766 (CNCM I-3848), Lactobacillus acidophilus NCC 2775 (CNCM I-3851), Lactobacillus acidophilus NCC 2619 (ATCC 700396), and combinations thereof.

31. A method of increasing the production of agmatine in the gastrointestinal tract of a subject in need thereof, the method comprising administering to the subject a composition comprising an isolated probiotic and arginine, the isolated probiotic comprising a bacterial strain having at least 90%, preferably at least 95%, sequence identity with a strain selected from Lactobacillus acidophilus NCC 2628 (CNCM I-2453), Lactobacillus acidophilus NCC 2766 (CNCM I-3848), Lactobacillus acidophilus NCC 2775 (CNCMI-3851) and Lactobacillus acidophilus NCC 2619 (ATCC 700396).

32. The method of claim 31, wherein the isolated probiotic comprises a bacterial strain selected from the group consisting of Lactobacillus acidophilus NCC2628 (CNCM I-2453), Lactobacillus acidophilus NCC 2766 (CNCM I-3848), Lactobacillus acidophilus NCC 2775 (CNCM I-3851), Lactobacillus acidophilus NCC 2619 (ATCC 700396), and combinations thereof.

33. The method of claim 31, wherein the composition is administered in an amount effective to produce agmatine from arginine in the gastrointestinal tract of the subject at a pH between about 4.0 and about 8.

0.

34. The method of claim 31, wherein the concentration of agmatine in the gastrointestinal tract of the subject is at least 20 μM 24 hours after administration of the composition to the subject.

35. The method of claim 31, wherein the gastrointestinal tract of the subject is the lower gastrointestinal tract of the subject.